Read the full Congress Program!

EADO

16th World Congress on Cancers of the Skin®

12th Congress of the European Association of Dermato-Oncology

Organized by Hubert Pehamberger and Christoph Hoeller

AUGUST 31– SEPTEMBER 3, 2016

VIENNA, AUSTRIA

FINAL PROGRAM

www.wccs2016.com

OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults2

Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients

with low tumour PD-L1 expression2

The first and only approved I-O combination offering superior efficacy versus YERVOY1,2

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 in the SmPC for how to report adverse reactions.

NAME OF THE MEDICINAL PRODUCT: OPDIVO 10 mg/mL concentrate for solution for infusion. Pharmacotherapeutic Group: Antineoplastic agents, monoclonal antibodies. ATC code: L01XC17 QUALITATIVE AND QUANTITATIVE COMPOSITION: Each mL of concentrate contains 10 mg of nivolumab. One vial of 4 mL contains 40 mg of nivolumab. One vial of 10 mL contains 100 mg of nivolumab. Nivolumab is produced in Chinese hamster ovary cells by recombinant DNA technology. List of excipients: Sodium citrate dihydrate, Sodium chloride, Mannitol (E421), Pentetic acid (diethylenetriaminepentaacetic acid), Polysorbate 80, Sodium hydroxide (for pH adjustment), Hydrochloric acid (for pH adjustment) Water for injections. THERAPEUTIC INDICATIONS: Melanoma: OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy,

an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1 in the SmPC). Non-Small Cell Lung Cancer (NSCLC): OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. OPDIVO as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 in the SmPC. MARKETING AUTHORISATION HOLDER: Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom. CONTACT IN AUSTRIA: Bristol-Myers Squibb GesmbH, Vienna, Tel. +43 1 60143 -0 NR, prescription only. DATE OF LAST REVISION: May 2016

Further information, especially in regards to special warnings and precautions for use, Interactions with other medicinal products or other forms of interaction, pregnancy and lactation as well as undesirable effects are to be extracted from the published Summary of Product Characteristics (SmPC).

ABBREVIATED SMPC:

I-O – Immuno-oncology

References: 1. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and lpilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015;373:23-34. 2. OPDIVO® Summary of Product Characteristics. Available at the booth.

Visit BMS at booth No22 to learn more

© 2016 Bristol-Myers Squibb Company1506AT16PR06864-01 06/16

105453 WCCS Vienna Congress Advert v3.0 2016.06.16.indd 1 16/06/2016 17:12

EADO

Congress Information

Societies and Contacts 2

Welcome Message 5

Acknowledgements 6

Information from A to Z 7

Public Transport Vienna 11

Hofburg Overview 12

Scientific Program

Wednesday, August 31, 2016 14

Thursday, September 1, 2016 19

Friday, September 2, 2016 33

Saturday, September 3, 2016 49

List of Chairs and Invited Speakers 54

Poster Exhibition 56

Industrial Exhibition

List of Exhibitors 85

Exhibition Floor Plan 84

FSA Disclosure Requirement 87

Table of Contents

SY SymposiumPL Plenary Lecture

FC Free CommunicationSAT Industry Symposium

OT Others

Session Types


Societies

PresidentGarbe, Claus

Vice-PresidentStratigos, Alexander

TreasurerHauschild, Axel

General SecretaryPeris, Ketty

Secretary for MembersMalvehy, Josep

Secretary for European IntegrationForsea, Anna-Maria

Past PresidentGrob, Jean-Jacques

Past PresidentPehamberger, Hubert

Societies and Contacts

Skin Cancer Foundation*

PresidentRobins, Perry

Senior Vice PresidentsAmonette, Rex A.Hale, Elizabeth K.Hanke, C. William Moy, Ronald L. Perez, Maritza I. Sarnoff, Deborah S.

Vice PresidentsGoldberg, Leonard H. Halpern, Allan C.Quintana, Adelle T.Weinkle, Susan H.

General CounselWeiner, Bennett Esq.

SecretaryRobins, Elizabeth Esq.

Executive DirectorLatore, Dan

Board MembersAlper, SibelArenberger, Peter Bataille, VéroniqueBylaitė-Bučinskienė, MatildaDel Marmol, VéroniqueDreno, BrigitteDummer, ReinhardForsea, Ana-MariaGarbe, ClausGrob, Jean-JacquesHarwood, CatherineHauschild, Axel Hoeller, ChristophKandolf-Sekulovic, Lidija Kaufmann, Roland Lebbé, CélesteMalvehy, JosepMoreno-Ramírez, DavidOlah, Judit Pehamberger, HubertPellacani, Giovanni Peris, KettyRobert, CarolineStockfleth, Eggert Stratigos, AlexanderVieira, RicardoWeinlich, GeorgZalaudek, Iris

European Association of Dermato Oncology (EADO)*

*According to the respective website

2

CON

GRE

SS IN

FORM

ATIO

N

European A ssoc ia t ion o fDermato Onco logy

EADO

Congress Information Societies and Contacts

© W

ienT

ouris

mus

/ Ch

ristia

n St

empe

r

Congress PresidentsHubert Pehamberger, MD Professor of DermatologyMedical Director RudolfinerhausMedical University ViennaE: [email protected]

Christoph Hoeller, MDProfessor of Dermatology Medical University ViennaDepartment of Dermatology Währinger Gürtel 18–20Vienna, Austria E: [email protected]

Legal Organizer (PCO)MCI Deutschland GmbH MCI | Berlin Office Markgrafenstrasse 56 10117 Berlin, Germany P: +49 (0)30 204590 F: +49 (0)30 2045950 E: [email protected]

Registration and AccommodationE: [email protected]

Exhibition and SponsoringE: [email protected]

Contacts

3

CON

GRE

SS IN

FORM

ATIO

N

Time Session Speaker

09:00 Welcome and introduction Professor Claus Garbe (Chair) Germany

09:15What lies beneath? Optimising

diagnosis of field cancerisation Dr Iris Zalaudek Austria

09:30AK and beyond: Tailored therapy

to optimise patient outcomesProfessor Jean-Jacques Grob France

09:45 Panel discussion All

09:55 Closing remarks Professor Claus Garbe (Chair) Germany

AGENDA

Please join us as we explore the concept of field cancerisation and personalised field therapy for the treatment of actinic keratosis (AK), with our renowned expert faculty who will discuss the current unmet needs in AK and the risk factors that may be linked to the recurrence of this condition and its progression to squamous cell carcinoma

Geheime Ratstube Hofburg Vienna, Austria

Chair: Professor Claus Garbe | Germany

Satellite symposium Thursday, 1st September, 09:00–10:00

MORE THAN MEETS THE EYE – TREATING ACTINIC KERATOSIS AND BEYOND

Release date: August 2016


Hubert Pehamberger Christoph Hoeller

Welcome Message

Dear Colleagues,The “World Congress on Cancers of the Skin” and the “Congress of the European Association of Dermato-Oncology” (EADO) have become major interdisciplinary meetings for clinicians and basic scientists working in the challenging fields of Melanoma and Non-Melanoma Skin Cancer. Both meetings will be held together as a Joint Meeting covering the entire spectrum of cutaneous malignancies.

It is our pleasure to host this unique Joint Meeting of the 16th World Congress on Cancers of the Skin and the 12th EADO conference in the historic Hofburg Conference Center in the heart of Vienna. We feel privileged and honored that many of the world’s leading investigators in the field will actively participate in this meeting. Clinicians and researchers will focus on the state of the art in prevention, recognition,

and treatment of cutaneous neoplasms covering Melanoma and Non Melanoma Skin Cancer as well as Lymphomas and Rare Skin Tumors.

As the organizers of this meeting we cordially invite you to share with us days of scientific communication in the beautiful city of Vienna.

© W

ienT

ouris

mus

/Chr

istia

n St

empe

r

5

CON

GRE

SS IN

FORM

ATIO

N


We are delighted to give special thanks to our main sponsors:

Acknowledgements

6

CON

GRE

SS IN

FORM

ATIO

N

Gold Sponsors

Platinum Sponsors

Silver Sponsor

Bronze Sponsors

BIOPHARMACEUTICALS, INC.Advancing a New Front

in theWar Against Cancer


AbstractsApproved abstracts have been published online as a supplement to the August issue of “Melanoma Research”. You may access these abstracts free of charge until August 2017 by visiting:: journals.lww.com/ melanomaresearch/pages/default.aspx

Act of GodIt is mutually agreed that in the event of total or partial cancellation of the congress due to fire, strike, natural disaster (either threatened or actual), government regulations or incidents not caused by the organizer, which would prevent its scheduled opening or continuance, the congress may be partially postponed or terminated as a whole. In this case, participants are not entitled to reclaim refunds on no account. Participants are obliged to have civil liability insurance.

Certificate of AttendanceAll registered participants will receive a certificate of attendance. You are able to print your certificate at the self-printing stations in the Hall on the ground floor.

Opening HoursFRI, September 2 12:00 PM–06:30 PM SAT, September 3 07:00 AM–01:00 PM

ClimateVienna belongs to the humid continental climate. In August the weather is warm. Average temperatures are 20°C during the day. At night the temperatures can decrease to 11°C.

Information from A to Z

Congress DocumentsRegistration fee for participants covers: admission to scientific sessions and satellite symposia, congress bag with congress documents, admission to the exhibition.

Congress Language The official language of the congress will be English. Simultaneous translation will not be provided.

Congress VenueHofburg Vienna Heldenplatz 1010 Vienna, AustriaP: +43 1 5873666F: +43 1 5356426

CurrencyThe official currency in Austria is Euro (EUR).

ElectricityIn Austria electricity is supplied at 220V, 50Hz. For some devices from abroad converters will be needed.

InsuranceThe congress organizers do not accept any liability for damages and/or losses of any kind which may be incurred by the congress participants or by any persons accompanying them. Delegates participate in all events at their risk. Participants are advised to take out insurances against loss, accidents or damage that could occur during the Congress. Verbal agreements will not be binding unless

7

CON

GRE

SS IN

FORM

ATIO

N

Congress Information Information from A to Z

they are confirmed in writing. Sole place of jurisdiction is Vienna. Austrian law is applicable.

GastronomyThe catering stations for the coffee and lunch breaks are located in the Hofburg Lounge, in the Hofburg Galerie and in the Seitengalerie. Participants will be offered snacks and beverages. Catering is not included in the registration fee.

Helpful Phone NumbersTaxi Vienna: +43 66 44 60 43 89Taxi 40100: +43 140 100Fire Service: 122Police: 133

Internet AccessFree wireless internet access is available in the venue. Therefore a password is required.

� Name: HofburgSecured � Password: wccs2016

Please ensure the wireless connection on your device is configured and your device is correctly protected for wireless usage. No technical support will be provided.

Liability DisclaimerThe organizers cannot be held liable for any hindrance or disruption of congress proceedings arising from political, social or economic events or any other unforeseen incidents beyond their control. The organizers will accept no liability for any personal injuries sustained or for loss or damage to property belonging to congress participants, either during or

as a result of the congress or during all events. Registration of a participant entails acceptance of these conditions.

Lost & FoundA Lost & Found box will be placed at the registration desk.

Media CheckThe media check is located in the Orchestergang on the first floor.Speakers are requested to hand in their presentations at least 3 hours before their talk. Speakers having a presentation during the first time slot in the morning are asked to hand in their slides the day before. Please do not bring a laptop or other media device to the session room.

Opening HoursWED, August 31 12:00 PM–06:00 PMTHU, September 1 07:00 AM–06:00 PMFRI, September 2 07:00 AM–06:00 PMSAT, September 3 07:00 AM–12:00 PM

Name BadgesThe name badge will be the official meeting document and should be worn at all times in order to gain entry to the meeting rooms and the exhibition halls. Admission to the conference will not be allowed without badge identification. In case of lost or for-gotten badges, an administration fee of €20 will be charged.

Parking FacilitiesThere are no parking slots available at the Congress Venue. Please use the parking garages nearby:

8

CON

GRE

SS IN

FORM

ATIO

N

v.forghieri

Evidenziato

v.forghieri

Evidenziato


Garage Robert Stolz-Platz (500 m)*Price: €3.80/1h (day price: €38)

Garage am Museumsquartier (Museumsplatz, 500m)*Price: €4/1h (day price: €22)

Parkgarage Rathauspark (Universitätsring, 500m)*Price: €4/1h (day price: €40)

* Opening hours: 24h/7 days a week

Photography, Audio, Video and Mobile Phone PolicyAudio, photo and video recording by any device (e.g. cameras, laptops, PDAs, mobile phones, watches) is strictly prohibited dur-ing all oral and poster sessions, unless prior permission is obtained from the congress organizer. Use of mobile phones is strictly prohibited during scientific sessions. Mobile phones must be switched off while attend-ing sessions.

Program ChangesThe organizer reserves the right to make changes if necessary. No full or partial refunds are made to the attendees in the event of cancellations or other changes in the program. Please note that changes will be posted at the registration desk and at the entrance of the session halls. Partici-pants will be informed about the changes.

Public TransportationVienna offers an efficient and modern system of public transportation (called VOR), including underground (U),

metropolitan train (S), trams and buses. There are also special night buses (N) which may be used with the standard tickets. You can purchase public transportation tickets at most tobacconists (Tabak-Trafik), VOR ticket offices, ticket distributor machines at underground stations and in some hotels; on the tram (machine in the 1st coach) and on the bus (from the driver). Tickets must be stamped at the “blue box” located inside the tram or bus; for underground and metropolitan train it is located at the barrier before accessing the platform.

RegistrationYou can still register online and directly in Vienna. However, waiting can be eased, if participants register online in advance. Pre-registered participants will receive a barcode which is required on-site in order to print the badge. Therefore, it is essential to have the barcode ready. Self-printing stations are located directly in front of the registration desk.

Registration DeskThe registration desk is situated in the Hall on the ground floor.P: +43 1 536 44 223

Opening HoursWED, August 31 12:00 PM–06:30 PMTHU, September 1 07:00 AM–06:30 PMFRI, September 2 07:00 AM–06:30 PMSAT, September 3 07:00 AM–01:00 PM


9

CON

GRE

SS IN

FORM

ATIO

N

v.forghieri

Evidenziato

v.forghieri

Evidenziato


Registration Fees Late/On-site FeesDelegates € 665Residents* € 300Students* € 190Accompanying person € 85Day ticket € 250

*Proof of current status needs to be provided along with the registration.

Social ProgramGet TogetherThe Get Together will take place on Wednesday, August 31 at 7:00 PM at the Hofburg Galerie in the Congress location.

Networking EveningThe Networking Evening will take place on Friday, September 2 at 08:00 PM. at Heuriger Werner Welser, Probusgasse 12, 1190 Vienna. The traditional Austrian

tavern (Heurigen) will deliver a marvellous atmosphere for the evening. You will appreciate the wonderful Viennese wines as well as various typical dishes. The bus-transfer to the location will start at 07:30 PM at Hofburg Vienna.

SmokingSmoking is strictly prohibited in the congress venue by law.

Time ZoneAustria belongs to the Central European Time Zone (GMT+1).

TippingIn many areas such as gastronomy, in taxis, at hairdressers, at service stations, tipping is traditionally expected. Usually, the tip amounts to about 5 to 10%, according to the degree of your satisfaction with the service rendered.


© W

ienT

ouris

mus

/Chr

istia

n St

empe

r

10

CON

GRE

SS IN

FORM

ATIO

N

v.forghieri

Evidenziato

v.forghieri

Evidenziato

v.forghieri

Evidenziato

Congress Information Public Transport Vienna

11

CON

GRE

SS IN

FORM

ATIO

N

Congress Information Hofburg Overview

Registration 1 Hofburg Foyer (Halle)

Sessions 2 Festsaal 3 Zeremoniensaal 4 Rittersaal 5 Geheime Ratstube

Industrial Exhibition 6 Hofburg Galerie 7 Seitengalerie 8 Oberes Platzl

Poster Exhibition 9 Marmorsaal 10 Antekammer

Media Check 11 Orchestergang

12

CON

GRE

SS IN

FORM

ATIO

N

SCIENTIFIC PROGRAM

Wednesday, August 31, 2016 14

Thursday, September 1, 2016 19

Friday, September 2, 2016 33

Saturday, September 3, 2016 49

List of Chairs and Speakers 54

Poster Exhibition 56

EADO

Scientific Program Wednesday, August 31, 2016

Festsaal Zeremoniensaal Rittersaal Geheime RatstubeSY1

Epidemiology of Skin Cancer, Public Education and Primary Prevention

01:30 PM–03:30 PM

SY2Biology of Skin Cancer

Development01:30 PM–03:30 PM

SY3Dermoscopy Part I Basics

01:30 PM–03:30 PM

Exhi

bito

n – H

ofbu

rg G

alerie

02:00 PM

03:00 PM

Coffe Break 03:30 PM–04:30 PM

SAT2Novartis Symposium: Melanoma Changing

Landscape: Individualized Decision Making

03:30 PM–04:30 PM

SAT1Merck-Pfizer Symposium:

Current and Potential Future Treatment Options for Merkel Cell Carcinoma

03:30 PM–04:30 PM

04:00 PM

PL1Plenary

04:30 PM–06:00 PM05:00 PM

06:00 PM OT1Opening Ceremony

06:00 PM–07:00 PM

07:00 PM OT2Get Together

(Hofburg Galerie)07:00 PM–09:30 PM

08:00 PM

09:00 PM

14

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


01:30 PM–03:30 PM SY1 SYMPOSIUM

Festsaal Epidemiology of Skin Cancer, Public Education and Primary Prevention

Chairs: P. Robins (USA)V. Del Marmol (Brussels, Belgium)

01:30 PM–01:50 PM SY1-1 Epidemiology of skin cancer worldwideA. Halpern (New York, USA)

01:50 PM–02:10 PM SY1-2 Skin cancer prevention in AustraliaM. Janda (Brisbane, Australia)

02:10 PM–02:30 PM SY1-3 Skin cancer prevention in the USA. Geller (Boston, USA)

02:30 PM–02:50 PM SY1-4 Euro-melanoma, a successful public awareness campaignV. Del Marmol (Brussels, Belgium)

02:50 PM–03:10 PM SY1-5 Is there a skin cancer epidemic in southern AmericaF. Stengel (Buenos Aires, Argentina)

03:10 PM–03:30 PM SY1-6 Skin cancer in the Middle European region P. Arenberger (Prague, Czech Republic)


Zeremoniensaal Biology of Skin Cancer Development

Chairs: M. Herlyn (Philadelphia, USA)B. Lichtenberger (Vienna, Austria)

01:30 PM–01:50 PM SY2-1 UV and carcinogenesis – one source, many mechanismsT. Schwarz (Kiel, Germany)

01:50 PM–02:10 PM SY2-2 Identification of a novel mutational signature in cutaneous SCC associated with chronic azathioprine exposureG. Inman (Dundee, UK)

02:10 PM–02:30 PM SY2-3 RG1-VLP – a chimeric virus-like particle vaccine for prevention of HPV-associated cancersR. Kirnbauer (Vienna, Austria)

02:30 PM–02:50 PM SY2-4 Melanozytes – why they can give rise to deadly tumors M. Herlyn (Philadelphia, USA)

15

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


02:50 PM–03:10 PM SY2-5 Keratinocytes and autophagy – a role in carcinogenesis?E. Tschachler (Vienna, Austria)

03:10 PM–03:25 PM SY2-6 Do fibroblasts have a role in cutaneous carcinogenesis?B. Lichtenberger (Vienna, Austria)


Rittersaal Dermoscopy Part I Basics

Chairs: I. Zalaudek (Graz, Vienna)H. Kittler (Vienna, Austria)

01:30 PM–01:50 PM SY3-1 The good: melanocytic nevi S. Puig (Barcelona, Spain)

01:50 PM–02:10 PM SY3-2 The bad: melanoma G. Argenziano (Napels, Italy)

02:10 PM–02:30 PM SY3-3 The ugly: seborrheic keratosis R. Hofmann-Wellenhof (Graz, Austria)

02:30 PM–02:50 PM SY3-4 The neglected: pigmented epithelial neoplasmsI. Zalaudek (Graz, Austria)

02:50 PM–03:10 PM SY3-5 The hidden: non-pigmented neoplasmsH. Kittler (Vienna, Austria)

03:10 PM–03:30 PM SY3-6 The eccentric: special sitesJ. Malvehy (Barcelona, Spain)

03:30 PM–04:30 PM COFFEE BREAK

16

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


03:30 PM–04:30 PM SAT1 MERCK-PFIZER ALLIANCE SYMPOSIUM

Geheime Ratstube Current and Potential Future Treatment Options for Merkel Cell CarcinomaLunch boxes will be provided.

Lead: M. Locker (Chicago, USA)

Chair: J. Becker (Essen, Germany)

03:30 PM–03:45 PM Welcome and introductionJ. Becker (Essen, Germany)

03:45 PM–03:55 PM SAT1-1 Metastatic Merkel cell carcinoma: current treatment landscapeC. Lebbé (Paris, France)

03:55 PM–04:20 PM SAT1-2 New treatment approaches for Merkel cell carcinomaI. Brownell (Bethesda, USA)

04:20 PM–04:30 PM Q&A and closeJ. Becker (Essen, Germany)

03:30 PM–04:30 PM SAT2 NOVARTIS SYMPOSIUM

Rittersaal Melanoma Changing Landscape: Individualized Decision Making

Chair: J.-J. Grob (Marseille, France)

03:30 PM–03:40 PM SAT2-1 Welcome and introduction. What have we learned from ASCO?J.- J. Grob (Marseille, France)

03:40 PM–04:00 PM SAT2-2 Primary and acquired resistance: What impact does this have on targeted and immunotherapies?J. Larkin (London, UK)

04:00 PM–04:20 PM SAT2-3 How can we use the data to individualize treatments?R. Gutzmer (Hannover, Germany)

04:20 PM–04:30 PM Panel discussion and Q&A

17

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


04:30 PM–06:00 PM PL1 PLENARY LECTURE

Festsaal Chairs: H. Pehamberger (Vienna, Austria)C. Hoeller (Vienna, Austria)K. Wolff (Vienna, Austria)

04:30 PM–05:15 PM PL1-1 Immunotherapy of melanoma – from revolution to evolution J. Weber (New York, USA)

05:15 PM–06:00 PM PL1-2 Targeted therapy of basal cell carcinoma – past, present and the future A. Sekulic (Phoenix, USA)

06:00 PM–07:00 PM OT1 OPENING CEREMONY

Festsaal Hubert Pehamberger, Congress President

Claus Garbe, President EADO

Perry Robins, President Skin Cancer Foundation

Markus Mueller, Rector Medical University of Vienna

Phili-Tango - Ensemble with members of the Vienna Philharmonic Orchestra

07:00 PM–09:30 PM OT2 GET TOGETHER

Hofburg Galerie

18

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

Scientific Program Thursday, September 1, 2016

Festsaal Zeremoniensaal Rittersaal Geheime Ratstube 08:00 AM SY4

Genetic Testing in Skin Cancer – Methods

and Strategies08:00 AM–08:55 AM

SY5Cutaneous Lymphoma IBiology, Epidemiology,

Genetic Research08:00 AM–08:55 AM

SY6Skin Cancer Centers –

What is the Worldwide Standard?

08:00 AM–08:55 AM

SY7Basics of (Cutaneous)

Immunology08:00 AM–08:55 AM

09:00 AM Coffee Break 09:00 AM–09:30 AM

SAT3LEO Pharma Breakfast Symposium: More than

Meets the Eye 9:00 AM–10:00 AM

Exhi

bito

n – H

ofbu

rg G

alerie

SY8Melanoma Therapy Drugs and Trials Current Status

I – Kinase Inhibitors09:30 AM–10:55 AM

SY10BCC Epidemiology, Biology, Genetics,

Clinical Data 09:30 AM–10:55 AM

SY9Surgery of Skin Cancer

Primaries 09:30 AM–10:55 AM10:00 AM SY11

Skin Cancer Biology 10:00 AM–10:55 AM

11:00 AM PL2 Genetics

11:00 AM–12:00 PM

12:00 PM

Lunch Break 12:00 PM–01:30 PM

SAT4AMGEN Lunch

Symposium: Advancing Immuno-Oncology with

an Intralesional Treatment12:15 PM–01:15 PM

01:00 PM

SY12Melanoma Therapy Drugs and Trials Current Status

II – Immunotherapy01:30 PM–02:50 PM

SY13Squamous Cell Carcinoma/

AK – Epidemiology, Biology, Local Therapies

01:30 PM–02:50 PM

SY14Open Questions in Dermatopathology

of Cutaneous Tumors01:30 PM–02:50 PM

SY15Sentinel Node Surgery

01:30 PM–02:50 PM02:00 PM

03:00 PM SAT5F. Hoffmann – La Roche Vienna

Coffeehouse Symposium: “Advanced melanoma:

Treat it personally” 03:00 PM–04:00 PM

Coffee Break 03:00 PM–04:15 PM

04:00 PMPL3

Plenary Melanoma04:15 PM–05:15 PM

05:00 PMSY16

Controversies: Is Immunotherapy the

Current Standard for Every Melanoma Patient? 05:20 PM–06:20 PM

SY17PDT

05:20 PM–06:20 PM

SY18Vaccines for

Cutaneous Tumors05:20 PM–06:20 PM

06:00 PM

19

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


08:00 AM–08:55 AM SY4 SYMPOSIUM

Festsaal Genetic Testing in Skin Cancer – Methods and Strategies

Chairs: J. Malvehy (Barcelona, Spain)M. C. Fargnoli (L’Aquila, Italy)

08:00 AM–08:25 AM SY4-1 Genetic testing in skin cancer – from specific to abundant G. McArthur (Melbourne, Australia)

08:25 AM–08:40 AM SY4-2 Genetic testing in daily practice – what’s feasible?M. C. Fargnoli (L’Aquila, Italy)

08:40 AM–08:55 AM SY4-3 Genetic testing for skin cancer susceptibility – did we come to an end? I. Okamoto (Vienna, Austria)


Zeremoniensaal Cutaneous Lymphoma IBiology, Epidemiology, Genetic Research

Chairs: J. Scarisbrick (Birmingham, UK)P. Quaglino (Torino, Italy)

08:00 AM–08:13 AM SY5-1 Pathogenetic concepts in T-cell lymphoma 2016S. Whittaker (London, UK)

08:13 AM–08:26 AM SY5-2 Sezary Syndrom and the EORTC translational research projects 2016M. H. Vermeer (Leiden, Netherlands)

08:26 AM–08:39 AM SY5-3 Results of the cutaneous lymphoma prognostic study (CLIPI)J. Scarisbrick (Birmingham, UK)

08:39 AM–08:55 AM SY5-4 The new WHO 2015 classification of cutaneous lymphomas R. Willemze (Leiden, Netherlands)

20

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Rittersaal Skin Cancer Centers – What is the Worldwide Standard?

Chairs: A.-M. Forsea (Bucharest, Romania)P. Mohr (Buxtehude, Germany)

08:00 AM–08:15 AM SY6-1 What should an ideal skin cancer center look like?P. Mohr (Buxtehude, Germany)

08:15 AM–08:30 AM SY6-2 What can we achieve in the light of current limitations?A.-M. Forsea (Bucharest, Romania)

08:30 AM–08:45 AM SY6-3 How can interdisciplinary cooperation maximize our patients benefit?C. Hoeller (Vienna, Austria)

08:45 AM–08:55 AM SY6-4 Panel discussion: What do we have to do to maximize patient benefit and research output in skin cancer centers?


Geheime Ratstube Basics of (Cutaneous) Immunology

Chairs: W. Weninger (Sidney, Australia)S. Grabbe (Mainz, Germany)

08:00 AM–08:25 AM SY7-1 Principles of cutaneous immunology S. Grabbe (Mainz, Germany)

08:25 AM–08:40 AM SY7-2 Trafficking of immune cells in the skin, implications for therapy W. Weninger (Sidney, Australia)

08:40 AM–08:55 AM SY7-3 The emerging role of resident memory T cells in protective immunity and inflammatory disease T. Kupper (Boston, USA)

09:00 AM–09:30 AM COFFEE BREAK

21

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

Copy

right

© 2

015

Mer

ck S

harp

& D

ohm

e Co

rp.,

a su

bsid

iary

of M

erck

& C

o., I

nc.,

Keni

lwor

th,

NJ,

USA

. All

right

s re

serv

ed.

06-1

7-O

NCO

-118

8131

-000

0. E

rste

llt: J

uni 2

016

KE

YN

OT

E-0

06

stu

dy

des

ign

: An

op

en-l

abel

, mu

ltic

ente

r, r

and

om

ized

, co

ntr

olle

d P

has

e 3

tria

l th

at in

clu

ded

pat

ien

ts w

ith

un

rese

ctab

le o

r m

etas

tati

c m

elan

om

a w

ho

wer

e n

aïve

to

ipili

mu

mab

an

d w

ho

had

rec

eive

d n

o m

ore

th

an 1

pri

or

syst

emic

th

erap

y. P

atie

nts

wit

h B

RA

F V

600E

mu

tan

t m

elan

om

a w

ere

no

t re

qu

ired

to

h

ave

rece

ived

pri

or

BR

AF

inh

ibit

or

ther

apy.

Pat

ien

ts w

ere

ran

do

miz

ed (1

:1:1

) to

rec

eive

KE

YT

RU

DA

® a

t a

do

se o

f 10

mg

/kg

eve

ry 2

(n

=27

9) o

r 3

wee

ks (

n=

277)

or

ipili

mu

mab

(n=

278)

. Th

e p

rim

ary

effi

cacy

ou

tco

me

mea

sure

s w

ere

ove

rall

surv

ival

(OS

) an

d p

rog

ress

ion

-fre

e su

rviv

al (P

FS; a

s as

sess

ed b

y In

teg

rate

d R

adio

log

y an

d O

nco

log

y A

sses

smen

t [I

RO

] re

view

usi

ng

Res

po

nse

Eva

luat

ion

Cri

teri

a In

So

lid T

um

ors

[R

EC

IST

1.1

]).1

a In

inte

nt-

to-t

reat

po

pu

lati

on

. bM

edia

n n

ot

reac

hed

.P

D-1

=p

rog

ram

med

dea

th r

ecep

tor-

1; Q

3W=

ever

y 3

wee

ks; Q

2W=

ever

y 2

wee

ks; H

R=

haz

ard

rat

io; C

I=co

nfi

den

ce in

terv

al.

KE

YT

RU

DA

® is

ind

icat

ed f

or

the

trea

tmen

t o

f p

atie

nts

wit

h u

nre

sect

able

or

met

asta

tic

mel

ano

ma.

Ref

eren

ce: 1

. Ro

ber

t C, S

chac

hte

r J,

Lon

g G

V, e

t al,

for

the

KE

YN

OT

E-00

6 in

vest

igat

ors.

Pem

bro

lizum

ab v

ersu

s ip

ilim

umab

in a

dva

nce

d m

elan

om

a. N

Eng

l J

Med

. 201

5;37

2(26

):252

1–25

32.

Bef

ore

pres

crib

ing

KEY

TRU

DA

®, p

leas

e re

ad th

e Pr

escr

ibin

g In

form

atio

n.

SUM

MA

RY O

F PR

OD

UCT

CH

ARA

CTER

ISTI

CS:

Nam

e of

the

Med

icin

al P

rodu

ct K

EYTR

UD

A®

50 m

g po

wde

r for

con

cent

rate

for s

olut

ion

for i

nfus

ion.

Qua

litat

ive

and

Qua

ntita

tive

Com

posi

tion

One

via

l of p

owde

r co

ntai

ns 5

0 mg

of p

embr

oliz

umab

. Aft

er re

cons

titut

ion,

1 m

l of c

once

ntra

te c

onta

ins

25 m

g of

pem

brol

izum

ab. P

embr

oliz

umab

is a

hum

anis

ed m

onoc

lona

l ant

i-pro

gram

med

cel

l dea

th-1

(PD

-1) a

ntib

ody

(IgG

4/ka

ppa

isot

ype

with

a s

tabi

lisin

g se

quen

ce a

ltera

tion

in th

e Fc

reg

ion)

pro

duce

d in

Chi

nese

ham

ster

ova

ry c

ells

by

reco

mbi

nant

DN

A te

chno

logy

. Lis

t of e

xcip

ient

s L-

His

tidin

e, L

-His

tidin

e hy

droc

hlor

ide

Mon

ohyd

rate

, Su

cros

e, P

olys

orba

te 8

0 Th

erap

eutic

indi

catio

ns K

EYTR

UD

A®

as

mon

othe

rapy

is in

dica

ted

for t

he tr

eatm

ent o

f adv

ance

d (u

nres

ecta

ble

or m

etas

tatic

) mel

anom

a in

adu

lts. C

ontr

aind

icat

ions

Hyp

erse

nsiti

vity

to th

e ac

tive

subs

tanc

e or

to a

ny o

f the

exc

ipie

nts

liste

d in

sec

tion

6.1.

Fer

tility

, pre

gnan

cy a

nd la

ctat

ion

Preg

nanc

y Th

ere

are

no d

ata

on th

e us

e of

pem

brol

izum

ab in

pre

gnan

t wom

en. A

nim

al re

prod

uctio

n st

udie

s ha

ve

not b

een

cond

ucte

d w

ith p

embr

oliz

umab

; how

ever

, in

mur

ine

mod

els

of p

regn

ancy

blo

ckad

e of

PD

-L1

sign

alin

g ha

s be

en s

how

n to

dis

rupt

tole

ranc

e to

the

foet

us a

nd to

res

ult i

n an

incr

ease

d fo

etal

loss

. The

se

resu

lts in

dica

te a

pot

entia

l ris

k, b

ased

on

its m

echa

nism

of a

ctio

n, th

at a

dmin

istr

atio

n of

pem

brol

izum

ab d

urin

g pr

egna

ncy

coul

d ca

use

foet

al h

arm

, inc

ludi

ng in

crea

sed

rate

s of

abo

rtio

n or

stil

lbirt

h. H

uman

imm

u-no

glob

ulin

s G

4 (Ig

G4)

are

kno

wn

to c

ross

the

plac

enta

l bar

rier a

nd p

embr

oliz

umab

is a

n Ig

G4;

ther

efor

e, p

embr

oliz

umab

has

the

pote

ntia

l to

be tr

ansm

itted

from

the

mot

her t

o th

e de

velo

ping

foet

us. P

embr

oliz

umab

sh

ould

not

be

used

dur

ing

preg

nanc

y un

less

the

clin

ical

con

ditio

n of

the

wom

an re

quire

s tr

eatm

ent w

ith p

embr

oliz

umab

. Wom

en o

f chi

ldbe

arin

g po

tent

ial s

houl

d us

e ef

fect

ive

cont

race

ptio

n du

ring

trea

tmen

t with

pe

mbr

oliz

umab

and

for a

t lea

st 4

mon

ths

afte

r the

last

dos

e of

pem

brol

izum

ab. B

reas

t-fe

edin

g It

is u

nkno

wn

whe

ther

pem

brol

izum

ab is

sec

rete

d in

hum

an m

ilk. S

ince

it is

kno

wn

that

ant

ibod

ies

can

be s

ecre

ted

in

hum

an m

ilk, a

risk

to th

e ne

wbo

rns/

infa

nts

cann

ot b

e ex

clud

ed. A

dec

isio

n sh

ould

be

mad

e w

heth

er to

dis

cont

inue

bre

ast-

feed

ing

or to

dis

cont

inue

pem

brol

izum

ab, t

akin

g in

to a

ccou

nt th

e be

nefit

of b

reas

t-fe

edin

g fo

r the

chi

ld a

nd th

e be

nefit

of p

embr

oliz

umab

ther

apy

for t

he w

oman

. Fer

tility

No

clin

ical

dat

a ar

e av

aila

ble

on th

e po

ssib

le e

ffec

ts o

f pem

brol

izum

ab o

n fe

rtili

ty. A

lthou

gh re

prod

uctiv

e an

d de

velo

pmen

tal t

oxic

ity

stud

ies

have

not

bee

n co

nduc

ted

with

pem

brol

izum

ab, t

here

wer

e no

not

able

eff

ects

in th

e m

ale

and

fem

ale

repr

oduc

tive

orga

ns in

mon

keys

bas

ed o

n 1-

mon

th a

nd 6

-mon

th re

peat

dos

e to

xici

ty s

tudi

es. P

harm

aco-

ther

apeu

tic g

roup

: Ant

ineo

plas

tic a

gent

s, m

onoc

lona

l ant

ibod

ies.

ATC

cod

e: L

01XC

18 M

arke

ting

Aut

hori

satio

n H

olde

r Mer

ck S

harp

& D

ohm

e Li

mite

d, H

ertf

ord

Road

, Hod

desd

on, H

ertf

ords

hire

EN

11 9

BU,

Uni

ted

King

dom

Dis

pens

ing:

ava

ilabl

e on

ly o

n pr

escr

iptio

n an

d on

ly in

pha

rmac

ies.

Info

rmat

ion

as o

f: A

pril

2016

For f

urth

er In

form

atio

n on

Pos

olog

y an

d m

etho

d of

adm

inis

trat

ion,

Spe

cial

war

ning

s an

d pr

ecau

tions

for u

se, I

nter

actio

n w

ith o

ther

med

icin

al p

rodu

cts

and

othe

r for

ms

of in

tera

ctio

n, E

ffec

ts o

n ab

ility

to d

rive

an

d us

e m

achi

nes,

Und

esir

able

eff

ects

, Ove

rdos

e, P

harm

acod

ynam

ic p

rope

rtie

s an

d Ph

arm

acok

inet

ic p

rope

rtie

s re

fer t

o th

e pu

blis

hed

sum

mar

y of

pro

duct

cha

ract

eris

tics.

KEY Inserat Start with Keytruda A4.indd 2 01.07.16 11:30

Th

e fi

rst

anti

–PD

-1 t

o d

emo

nst

rate

su

per

ior

over

all s

urv

ival

vs

ipili

mu

mab

S

TA

RT

WIT

H K

EY

TR

UD

AFo

r p

atie

nts

wit

h a

dva

nce

d m

elan

om

a

68%

1-y

ear

esti

mat

ed o

vera

ll su

rviv

al r

ate

vs 5

8% w

ith

ipili

mu

mab

a,b

H

R (

95%

CI)

R

isk

red

uct

ion

vs ip

ilim

um

ab

vs ip

ilim

um

ab

P v

alu

e

KE

YT

RU

DA

10

mg

/kg

Q3W

0.

69 (

0.52

–0.9

0)

31%

0.

0035

8K

EY

TR

UD

A 1

0 m

g/k

g Q

2W

0.63

(0.

47–0

.83)

37

%

0.00

052

Ipil

imu

mab

Kap

lan

-Mei

er c

urv

e fo

r o

vera

ll su

rviv

al

by

trea

tmen

t ar

m.


Copy

right

© 2

015

Mer

ck S

harp

& D

ohm

e Co

rp.,

a su

bsid

iary

of M

erck

& C

o., I

nc.,

Keni

lwor

th,

NJ,

USA

. All

right

s re

serv

ed.

06-1

7-O

NCO

-118

8131

-000

0. E

rste

llt: J

uni 2

016

KE

YN

OT

E-0

06

stu

dy

des

ign

: An

op

en-l

abel

, mu

ltic

ente

r, r

and

om

ized

, co

ntr

olle

d P

has

e 3

tria

l th

at in

clu

ded

pat

ien

ts w

ith

un

rese

ctab

le o

r m

etas

tati

c m

elan

om

a w

ho

wer

e n

aïve

to

ipili

mu

mab

an

d w

ho

had

rec

eive

d n

o m

ore

th

an 1

pri

or

syst

emic

th

erap

y. P

atie

nts

wit

h B

RA

F V

600E

mu

tan

t m

elan

om

a w

ere

no

t re

qu

ired

to

h

ave

rece

ived

pri

or

BR

AF

inh

ibit

or

ther

apy.

Pat

ien

ts w

ere

ran

do

miz

ed (1

:1:1

) to

rec

eive

KE

YT

RU

DA

® a

t a

do

se o

f 10

mg

/kg

eve

ry 2

(n

=27

9) o

r 3

wee

ks (

n=

277)

or

ipili

mu

mab

(n=

278)

. Th

e p

rim

ary

effi

cacy

ou

tco

me

mea

sure

s w

ere

ove

rall

surv

ival

(OS

) an

d p

rog

ress

ion

-fre

e su

rviv

al (P

FS; a

s as

sess

ed b

y In

teg

rate

d R

adio

log

y an

d O

nco

log

y A

sses

smen

t [I

RO

] re

view

usi

ng

Res

po

nse

Eva

luat

ion

Cri

teri

a In

So

lid T

um

ors

[R

EC

IST

1.1

]).1

a In

inte

nt-

to-t

reat

po

pu

lati

on

. bM

edia

n n

ot

reac

hed

.P

D-1

=p

rog

ram

med

dea

th r

ecep

tor-

1; Q

3W=

ever

y 3

wee

ks; Q

2W=

ever

y 2

wee

ks; H

R=

haz

ard

rat

io; C

I=co

nfi

den

ce in

terv

al.

KE

YT

RU

DA

® is

ind

icat

ed f

or

the

trea

tmen

t o

f p

atie

nts

wit

h u

nre

sect

able

or

met

asta

tic

mel

ano

ma.

Ref

eren

ce: 1

. Ro

ber

t C, S

chac

hte

r J,

Lon

g G

V, e

t al,

for

the

KE

YN

OT

E-00

6 in

vest

igat

ors.

Pem

bro

lizum

ab v

ersu

s ip

ilim

umab

in a

dva

nce

d m

elan

om

a. N

Eng

l J

Med

. 201

5;37

2(26

):252

1–25

32.

Bef

ore

pres

crib

ing

KEY

TRU

DA

®, p

leas

e re

ad th

e Pr

escr

ibin

g In

form

atio

n.

SUM

MA

RY O

F PR

OD

UCT

CH

ARA

CTER

ISTI

CS:

Nam

e of

the

Med

icin

al P

rodu

ct K

EYTR

UD

A®

50 m

g po

wde

r for

con

cent

rate

for s

olut

ion

for i

nfus

ion.

Qua

litat

ive

and

Qua

ntita

tive

Com

posi

tion

One

via

l of p

owde

r co

ntai

ns 5

0 mg

of p

embr

oliz

umab

. Aft

er re

cons

titut

ion,

1 m

l of c

once

ntra

te c

onta

ins

25 m

g of

pem

brol

izum

ab. P

embr

oliz

umab

is a

hum

anis

ed m

onoc

lona

l ant

i-pro

gram

med

cel

l dea

th-1

(PD

-1) a

ntib

ody

(IgG

4/ka

ppa

isot

ype

with

a s

tabi

lisin

g se

quen

ce a

ltera

tion

in th

e Fc

reg

ion)

pro

duce

d in

Chi

nese

ham

ster

ova

ry c

ells

by

reco

mbi

nant

DN

A te

chno

logy

. Lis

t of e

xcip

ient

s L-

His

tidin

e, L

-His

tidin

e hy

droc

hlor

ide

Mon

ohyd

rate

, Su

cros

e, P

olys

orba

te 8

0 Th

erap

eutic

indi

catio

ns K

EYTR

UD

A®

as

mon

othe

rapy

is in

dica

ted

for t

he tr

eatm

ent o

f adv

ance

d (u

nres

ecta

ble

or m

etas

tatic

) mel

anom

a in

adu

lts. C

ontr

aind

icat

ions

Hyp

erse

nsiti

vity

to th

e ac

tive

subs

tanc

e or

to a

ny o

f the

exc

ipie

nts

liste

d in

sec

tion

6.1.

Fer

tility

, pre

gnan

cy a

nd la

ctat

ion

Preg

nanc

y Th

ere

are

no d

ata

on th

e us

e of

pem

brol

izum

ab in

pre

gnan

t wom

en. A

nim

al re

prod

uctio

n st

udie

s ha

ve

not b

een

cond

ucte

d w

ith p

embr

oliz

umab

; how

ever

, in

mur

ine

mod

els

of p

regn

ancy

blo

ckad

e of

PD

-L1

sign

alin

g ha

s be

en s

how

n to

dis

rupt

tole

ranc

e to

the

foet

us a

nd to

res

ult i

n an

incr

ease

d fo

etal

loss

. The

se

resu

lts in

dica

te a

pot

entia

l ris

k, b

ased

on

its m

echa

nism

of a

ctio

n, th

at a

dmin

istr

atio

n of

pem

brol

izum

ab d

urin

g pr

egna

ncy

coul

d ca

use

foet

al h

arm

, inc

ludi

ng in

crea

sed

rate

s of

abo

rtio

n or

stil

lbirt

h. H

uman

imm

u-no

glob

ulin

s G

4 (Ig

G4)

are

kno

wn

to c

ross

the

plac

enta

l bar

rier a

nd p

embr

oliz

umab

is a

n Ig

G4;

ther

efor

e, p

embr

oliz

umab

has

the

pote

ntia

l to

be tr

ansm

itted

from

the

mot

her t

o th

e de

velo

ping

foet

us. P

embr

oliz

umab

sh

ould

not

be

used

dur

ing

preg

nanc

y un

less

the

clin

ical

con

ditio

n of

the

wom

an re

quire

s tr

eatm

ent w

ith p

embr

oliz

umab

. Wom

en o

f chi

ldbe

arin

g po

tent

ial s

houl

d us

e ef

fect

ive

cont

race

ptio

n du

ring

trea

tmen

t with

pe

mbr

oliz

umab

and

for a

t lea

st 4

mon

ths

afte

r the

last

dos

e of

pem

brol

izum

ab. B

reas

t-fe

edin

g It

is u

nkno

wn

whe

ther

pem

brol

izum

ab is

sec

rete

d in

hum

an m

ilk. S

ince

it is

kno

wn

that

ant

ibod

ies

can

be s

ecre

ted

in

hum

an m

ilk, a

risk

to th

e ne

wbo

rns/

infa

nts

cann

ot b

e ex

clud

ed. A

dec

isio

n sh

ould

be

mad

e w

heth

er to

dis

cont

inue

bre

ast-

feed

ing

or to

dis

cont

inue

pem

brol

izum

ab, t

akin

g in

to a

ccou

nt th

e be

nefit

of b

reas

t-fe

edin

g fo

r the

chi

ld a

nd th

e be

nefit

of p

embr

oliz

umab

ther

apy

for t

he w

oman

. Fer

tility

No

clin

ical

dat

a ar

e av

aila

ble

on th

e po

ssib

le e

ffec

ts o

f pem

brol

izum

ab o

n fe

rtili

ty. A

lthou

gh re

prod

uctiv

e an

d de

velo

pmen

tal t

oxic

ity

stud

ies

have

not

bee

n co

nduc

ted

with

pem

brol

izum

ab, t

here

wer

e no

not

able

eff

ects

in th

e m

ale

and

fem

ale

repr

oduc

tive

orga

ns in

mon

keys

bas

ed o

n 1-

mon

th a

nd 6

-mon

th re

peat

dos

e to

xici

ty s

tudi

es. P

harm

aco-

ther

apeu

tic g

roup

: Ant

ineo

plas

tic a

gent

s, m

onoc

lona

l ant

ibod

ies.

ATC

cod

e: L

01XC

18 M

arke

ting

Aut

hori

satio

n H

olde

r Mer

ck S

harp

& D

ohm

e Li

mite

d, H

ertf

ord

Road

, Hod

desd

on, H

ertf

ords

hire

EN

11 9

BU,

Uni

ted

King

dom

Dis

pens

ing:

ava

ilabl

e on

ly o

n pr

escr

iptio

n an

d on

ly in

pha

rmac

ies.

Info

rmat

ion

as o

f: A

pril

2016

For f

urth

er In

form

atio

n on

Pos

olog

y an

d m

etho

d of

adm

inis

trat

ion,

Spe

cial

war

ning

s an

d pr

ecau

tions

for u

se, I

nter

actio

n w

ith o

ther

med

icin

al p

rodu

cts

and

othe

r for

ms

of in

tera

ctio

n, E

ffec

ts o

n ab

ility

to d

rive

an

d us

e m

achi

nes,

Und

esir

able

eff

ects

, Ove

rdos

e, P

harm

acod

ynam

ic p

rope

rtie

s an

d Ph

arm

acok

inet

ic p

rope

rtie

s re

fer t

o th

e pu

blis

hed

sum

mar

y of

pro

duct

cha

ract

eris

tics.



09:00 AM–10:00 AM SAT3 LEO-PHARMA BREAKFAST SYMPOSIUM

Geheime Ratstube More than Meets the Eye – Treating Actinic Keratosis (AK) and Beyond

Chair: C. Garbe (Tuebingen, Germany)

09:00 AM–09:15 AM Welcome and introductionC. Garbe (Tuebingen, Germany)

09:15 AM–09:30 AM SAT3-1 What lies beneath? Optimising diagnosis of field cancerisationI. Zalaudek (Graz, Austria)

09:30 AM–09:45 AM SAT3-2 AK and beyond: Tailored therapy to optimise patient outcomesJ.-J. Grob (Marseille, France)

09:45 AM–09:55 AM SAT3-3 Panel discussion

09:55 AM–10:00 AM Closing remarks and wrap upC. Garbe (Tuebingen, Germany)


Festsaal Melanoma Therapy Drugs and Trials Current Status I – Kinase Inhibitors

Chair: A. Hauschild (Kiel, Germany)

09:30 AM–09:47 AM SY8-1 Vem/CobimetinibG. McArthur (Melbourne, Australia)

09:47 AM–10:04 AM SY8-2 Dabrafenib/Trametinib A. Hauschild (Kiel, Germany)

10:04 AM–10:21 AM SY8-3 Kinase inhibitors for N-ras mutated patients J.-J. Grob (Marseille, France)

10:21 AM–10:38 AM SY8-4 Kinase inhibitors for rare mutation subgroups D. Schadendorf (Essen, Germany)

10:38 AM–10:55 AM SY8-5 Identification of prognostic subgroups for overall survival in patients (pts) with BRAFV600-mutated metastatic melanoma treated with vemurafenib ± cobimetinib: a pooled exploratory analysis of the BRIM-2, BRIM-3, BRIM-7, and coBRIM studiesA. Hauschild (Kiel, Germany)

24

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Rittersaal Surgery of Skin Cancer Primaries

Chairs: F. Roka (Vienna, Austria)R. Kaufmann (Frankfurt, Germany)

09:30 AM–09:50 AM SY9-1 Current standards for the management of primary skin cancer lesions in Europe R. Kaufmann (Frankfurt, Germany)

09:50 AM–10:10 AM SY9-2 Current standards for the management of primary skin cancer lesions in the US J. Gershenwald (Houston, USA)

10:10 AM–10:30 AM SY9-3 The role of mohs surgery in the management of primary skin cancer lesionsJ. Alcalay (Tel Aviv, Israel)

10:30 AM–10:55 AM SY9-4 Managment of primary lesions of rare skin tumors F. Roka (Vienna, Austria)


Zeremoniensaal BCC Epidemiology, Biology, Genetics, Clinical Data

Chairs: H. Hahn (Tuebingen, Germany)R. Kunstfeld (Vienna, Austria)

09:30 AM–09:50 AM SY10-1 Man’s most common tumor – the BCC epidemic A. Stratigos (Athens, Greece)

09:50 AM–10:10 AM SY10-2 Gorlin-Goltz syndromH. Hahn (Tuebingen, Germany)

10:10 AM–10:25 AM SY10-3 Which open questions in BCC biology will we have to answer in the future?A. Sekulic (Phoenix, USA)

10:25 AM–10:40 AM SY10-4 Use of vismodegib in the real world: analysis of a US insurance claims databaseC. Sima (San Francisco, USA)

10:40 AM–10:55 AM SY10-5 Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis R. Dummer (Zuerich, Switzerland)

25

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Geheime Ratstube Skin Cancer Biology

Chairs: V. Paulitschke (Vienna, Austria)D. Schramek (Toronto, Canada)

10:00 AM–10:20 AM SY11-1 The role of ETS transcription factors in SCC developmentD. Schramek (Toronto, Canada)

10:20 AM–10:40 AM SY11-2 Defining the mode of melanoma heterogeneity and drug sensitivity by real-time cell cycle imagingN. Haass (Queensland, Australia)

10:40 AM–10:55 AM SY11-3 Proteomics to reveal resistance mechanisms beyond genetic changesV. Paulitschke (Vienna, Austria)

11:00 AM–12:00 PM PL2 PLENARY LECTURE

Festsaal Genetics

Chairs: A. Halpern (New York, USA)C. Garbe (Tuebingen, Germany)

11:00 AM–11:30 AM PL2-1 Genetics of Nevi – what do they tell us about melanoma?B. Bastian (San Francisco, USA)

11:30 AM–12:00 AM PL2-2 Mutanome specific personalized vaccination U. Sahin (Mainz, Germany)

12:00 PM–01:30 PM LUNCH BREAK

26

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


12:15 PM–01:15 PM SAT4 AMGEN LUNCH SYMPOSIUM

Zeremoniensaal Advancing Immuno-Oncology with an Intralesional Treatment

Chair: H. Pehamberger (Vienna, Austria)

12:15 PM–12:20 PM Welcome and introductionH. Pehamberger (Vienna, Austria)

12:20 PM–12:40 PM SAT4-1 Igniting the immune response to target the tumorC. Hoeller (Vienna, Austria)

12:40 PM–01:00 PM SAT4-2 Talimogene laherparepvec (‘T-VEC’)* in clinical practiceO. Michielin (Geneva, Switzerland)

01:00 PM–01:10 PM Q&A

01:10 PM–01:15 PM Summary and close

* ▼ Subject to additional monitoring. This will allow quick identification of new safety information.


Festsaal Melanoma Therapy Drugs and Trials Current Status II – Immunotherapy

Chairs: B. Dreno (Nantes, France)J. Weber (Tampa, USA)

01:30 PM–01:50 PM SY12-1 PD-1R. Dummer (Zuerich, Switzerland)

01:50 PM–02:10 PM SY12-2 Vaccines and cell based therapiesB. Dreno (Nantes, France)

02:10 PM–02:30 PM SY12-3 Novel immunotherapies and combinationsJ. Weber (Tampa, USA)

02:30 PM–02:40 PM SY12-4 Efficacy and quality of life outcomes in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase III trial (CheckMate 067) D. Schadendorf (Essen, Germany)

02:40 PM–02:50 PM SY12-5 Patterns of clinical response in talimogene laherparepvec (T-VEC) treated patients with stage IIIB–IVM1a melanoma in the OPTiM phase III trial K. Harrington (London, UK)

27

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Zeremoniensaal Squamous Cell Carcinoma/AK-Epidemiology, Biology, Local Therapies

Chairs: A. Handisurya (Vienna, Austria)G. Hofbauer (Zuerich, Switzerland)

01:30 PM–01:45 PM SY13-1 From UV to SCC – insights into the biology of field cancerization E. Stockfleth (Bochum, Germany)

01:45 PM–02:00 PM SY13-2 Beyond UV – viral carcinogenesis in SCCA. Handisurya (Vienna, Austria)

02:00 PM–02:20 PM SY13-3 Topical therapy of NMSC R. Kunstfeld (Vienna, Austria)

02:20 PM–02:35 PM SY13-4 Outcome evaluation of local therapies – which endpoints show the real effect?G. Hofbauer (Zuerich, Switzerland)

02:35 PM–02:50 PM SY13-5 Structured expert consensus on actinic keratosis: an up-to-date treatment algorithm P. Calzavara-Pinton (Brescia, Italy)


Rittersaal Open Questions in Dermatopathology of Cutaneous Tumors

Chairs: M. C. Mihm (Boston, USA)P. Petzelbauer (Vienna, Austria)

01:30 PM–01:55 PM SY14-1 Open questions in the histopathology of cutaneous tumors 2016M. C. Mihm (Boston, USA)

01:55 PM–02:13 PM SY14-2 Desmoplastic melanomaK. J. Busam (New York, USA)

02:13 PM–02:31 PM SY14-3 Spitzoid melanocytic neoplasmsR. L. Barnhill (Paris, France)

02:31 PM–02:50 PM SY14-4 Open questions and standards in the pathology of cutaneous SCCA. Sober (Boston, USA)

28

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Geheime Ratstube Setinel Node Surgery

Chairs: A. Testori (Milano, Italy)M. Gnant (Vienna, Austria)

01:30 PM–01:50 PM SY15-1 Sentinel node in melanoma – the evidence behind the methodM. Ross (Houston, USA)

01:50 PM–02:10 PM SY15-2 Lessons learned from sentinel node in breast cancerM. Gnant (Vienna, Austria)

02:10 PM–02:30 PM SY15-3 Do we need to perform CLND after sentinel?C. Garbe (Tuebingen, Germany)

02:30 PM–02:50 PM SY15-4 Sentinel node in skin cancer beyond melanomaJ. Gershenwald (Houston, USA)


03:00 PM–04:00 PM SAT5 F. HOFFMANN-LA ROCHE LTD. VIENNA COFFEEHOUSE SYMPOSIUM

Zeremoniensaal Advanced melanoma: Treat it personally Optimising outcomes with targeted therapies in advanced melanoma in your clinical practice

Chair: J. Larkin (London, UK)

03:00 PM–03:15 PM SAT5-1 The current treatment landscape in advanced melanoma”J. Larkin (London, UK)

03:15 PM–03:55 PM SAT5-2 Summary and close J. Larkin (London, UK)

29

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


04:15 PM–05:15 PM PL3 PLENARY LECTURE

Festsaal Melanoma

Chairs: D. Schadendorf (Essen, Germany)G. McArthur (Brisbane, Australia)

04:15 PM–04:45 PM PL3-1 Combination therapies for skin cancer – where do we go?C. Blank (Amsterdam, Netherlands)

04:45 PM–05:15 PM PL3-2 Biomarkers for melanoma treatment – how will they impact our treatment decisions?O. Michielin (Lausanne, Switzerland)


Festsaal Controversies: Is Immunotherapy the Current Standard for Every Melanoma Patient? Pro/Con

Chairs: R. Dummer (Zuerich, Switzerland)P. Arenberger (Prague, Czech Republic)

05:20 PM–05:40 PM SY16-1 ProJ. Larkin (London, UK)

05:40 PM–06:00 PM SY16-2 ContraO. Michielin (Lausanne, Switzerland)

06:00 PM–06:20 PM Discussion with the audience


Zeremoniensaal PDT

Chairs: S. Radakovic (Vienna, Austria)R.-M. Szeimies (Recklinghausen, Germany)

05:20 PM–05:35 PM SY17-1 Topical photodynamic therapy in dermatology – how does it work?L. Braathen (Bern, Switzerland)

05:35 PM–05:50 PM SY17-2 PDT for skin cancer – what should we treat and what not?E. Sotiriou (Thessaloniki, Greece)

05:50 PM–06:05 PM SY17-3 Day-light PDT – a major breakthrough in dermatological PDT?R.-M. Szeimies (Recklinghausen, Germany)

06:05 PM–06:20 PM SY17-4 PDT-associated pain – are there means for relief?S. Radakovic (Vienna, Austria)

v

Read JDDG on the GoApp available for iPad®, iPhone® and iPod Touch®

Scan the QR code, or visit your App Store® online to download the app today

Experience an entirely new browsing and reading experience

• Convenient access to articles anytime, anywhere

• Quick navigation to any section of the app

• Immediate access to new content

• Select keywords for tailored content alerts

• Downloadissuestoreadoffline,orshareimportantarticles

• Enhanced search across all downloaded content

• Sync your favorite app content across devices via iCloud®

23

98

07

30

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

v

Read JDDG on the GoApp available for iPad®, iPhone® and iPod Touch®

Scan the QR code, or visit your App Store® online to download the app today

Experience an entirely new browsing and reading experience

• Convenient access to articles anytime, anywhere

• Quick navigation to any section of the app

• Immediate access to new content

• Select keywords for tailored content alerts

• Downloadissuestoreadoffline,orshareimportantarticles

• Enhanced search across all downloaded content

• Sync your favorite app content across devices via iCloud®

23

98

07



Rittersaal Vaccines for Cutaneous Tumors

Chairs: U. Sahin (Mainz, Germany)G. Schuler (Erlangen, Germany)

05:20 PM–05:40 PM SY18-1 Vaccines for melanoma – time for a comeback?G. Schuler (Erlangen, Germany)

05:40 PM–06:00 PM SY18-2 Oncolytic viruses: vehicles for endogenus vaccination?R. Andtbacka (Salt Lake City, USA)

06:00 PM–06:20 PM SY18-3 RNA based mutanome specific vaccines – a true personalized therapyU. Sahin (Mainz, Germany)

05:20 PM–06:20 PM PW1 POSTERWALK

Marmorsaal/ Antekammer

Melanoma P001- P099Late-Breaking P206 - P219

32

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

Scientific Program Friday, September 2, 2016

33

SCIE

NTI

FIC

PRO

GR

AM

Festsaal Zeremoniensaal Rittersaal Geheime Ratstube 08:00 AM SY19

Controversies: Is there a Dysplastic Nevus?

08:00 AM–08:55 AM

SY20Chemotherapy of Skin Cancers – Does it Still

Have a Role in Our Algorithms?

08:00 AM–08:55 AM

SY21Cutaneous Side Effects

of Oncological Drugs08:00 AM–08:55 AM

FC1Free Communications:

Melanoma08:00 AM–08:55 AM

09:00 AM SY22Neo-adjuvant Treatment

in Skin Cancer Patients09:00 AM–10:30 AM

SY23Cutaneous Lymphoma II –

Therapy Update09:00 AM–10:30 AM

SY24Genetics of Skin Cancer

09:00 AM–10:30 AM

SY25Dermosocopy II Experts

09:00 AM–10:30 AM

Exhi

bito

n – H

ofbu

rg G

alerie

10:00 AM

Coffee Break 10:30 AM–11:00 AM

11:00 AM PL4Cutaneous Lymphoma,

New Drugs11:00 AM–12:00 PM

12:00 PM

Lunch Break/Exhibition12:00 PM–01:15 PM

SAT6Lunch Symposium

Bristol-Myers Squibb:Immuno Oncology for

Melanoma: What’s new?12:15 AM–01:15 PM

01:00 PM

SY26How to Overcome Drug

Resistance01:30 PM–02:50 PM

SY27Systemic Treatment of Non-Melanoma

Skin Cancer 01:30 PM–02:50 PM

SY28Tumor Immunology01:30 PM–02:50 PM

SY29What’s a Drugs Value?01:30 PM–02:50 PM

02:00 PM

03:00 PM SAT7MSD Vienna Coffeehouse

Symposium:Great Debates of Immuno-

Oncology Therapies in Advanced Melanoma

03:00 PM–04:00 PM

Coffee Break 03:00 PM–04:00 PM

04:00 PM SY30UV-Protection,Vitamin D and

Photoaging04:05 PM–05:25 PM

SY31Melanoma Surgery Lymph

Nodes to Distant 04:05 PM–05:25 PM

SY32Smart Sequencing or

Combination Therapy – in Search for the Best

Strategy04:05 PM–05:25 PM

SY33Orphan Skin Cancer

– Epidemiology, Histopathology, Biology,

Therapy 04:05 PM–05:25 PM

05:00 PM

SY34Controversies: Sentinel Node and Completion

Lymph Node Dissection – Standard of Care?

05:30 PM–06:30 PM

SY35Skin Cancer in Special

Patient Subgroups05:30 PM–06:30 PM

SY36Locoregional Therapy of Melanoma Metastases

05:30 PM–06:30 PM

SY37Psychodermatooncology

05:30 PM–06:30 PM06:00 PM

08:00 PM OT3 Networking Evening (Heuriger)

08:00 PM

WED

THU

FRI

SAT

INDE

XPO

STER

CURRENTLY ENROLLING: JAVELIN Merkel 200(First-line Cohort)A Phase 2, open-label, multicenter trial to investigate the clinical activity and safety of avelumab* (MSB0010718C) in subjects with metastatic Merkel cell carcinoma

FOR MORE INFORMATION: www.clinicaltrials.gov (NCT02155647)

The JAVELIN clinical trial program studies avelumab in Phases 1-3, both as monotherapy and in combination with other agents.

The program includes diseases with large patient populations as well as rare diseases with high unmet needs.

Trials are currently enrolling patients with†:

• Merkel Cell Carcinoma (MCC)

• Hodgkin’s lymphoma

• Renal Cell Carcinoma (RCC)

• Melanoma

• Non-Small Cell Lung Cancer (NSCLC)

• Squamous Cell Carcinoma of the Head and Neck (SCCHN)

• Ovarian cancer

• Adenocarcinoma of the stomach or of the gastroesophageal junction

• Urothelial cancer

June 2016 US-AVL-0116-0004(1)

Avelumab is an investigational agent.

* Avelumab is the nonproprietary name for the anti-PD-L1 monoclonal antibody (MSB0010718C).† NCT02155647, NCT02603419, NCT02684006, NCT02493751, NCT02554812, NCT02395172, NCT02576574, NCT02584634, NCT02580058, NCT02625610, NCT02625623, NCT01772004, NCT02603432

This information is current as of June 2016.

US_AVL_0116_0004_1_R01_APDL_WCCS_Jav_Ad_Merkel_200.indd 1 6/8/16 4:07 PM



Festsaal Controversies: Is There a Dysplastic Nevus?

Chairs: P. Tschandl (Vienna, Austria)C. Hoeller (Vienna, Austria)

08:00 AM–08:20 AM SY19-1 ProB. Bastian (San Francisco, USA)

08:20 AM–08:40 AM SY19-2 ContraH. Kittler (Vienna, Austria)

08:40 AM–08:55 AM Discussion with the audience


Zeremoniensaal Chemotherapy of Skin Cancers – Does It Still Have a Role in Our Algorithms?

Chairs: P. Lorigan (Manchester, UK)R. Gutzmer (Hanover, Germany)

08:00 AM–08:13 AM SY20-1 Chemotherapy for melanoma – last resort or still an option? P. Lorigan (Manchester, UK)

08:13 AM–08:26 AM SY20-2 Chemotherapy for metastatic SCCR. Gutzmer (Hanover, Germany)

08:26 AM–08:39 AM SY20-3 Chemotherapy for cutaneous lymphomasL. Geskin (New York, USA)

08:39 AM–08:55 AM SY20-4 Chemotherapy in the treatment of orphan skin cancersR. Loewe (Vienna, Austria)


Rittersaal Cutaneous Side Effects of Oncological Drugs

Chairs: C. Lebbé (Paris, France)V. Sibaud (Toulouse, France)

08:00 AM–08:30 AM SY21-1 Cutaneous side effects of drugs in general oncologyV. Sibaud (Toulouse, France)

08:30 AM–08:55 AM SY21-2 Cutaneous side effects of novel PI3K inhibitors in mono- and combination-therapy K. Schindler (Vienna, Austria)

35

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


08:00 AM–08:55 AM FC1 FREE COMMUNICATIONS

Geheime Ratstube Melanoma

Chairs: P. Petzelbauer (Vienna, Austria)M. Herlyn (Philadelphia, USA)

08:00 AM–08:12 AM FC1-1 The role of the lymphovasculature during skin cancer developmentP. Petzelbauer (Vienna, Austria)

08:12 AM–08:24 AM FC1-2 Wnt signalling as a metabolic regulator in melanoma cells V. Sherwood (Dundee, UK)

08:24 AM–08:36 AM FC1-3 Modeling Wnt secretion in cutaneous squamous cell carcinoma K. I. Kober (Heidelberg, Germany)

08:36 AM–08:48 AM FC1-4 Upregulated sonic hedgehog activity drives the development of congenital nevi A. Chitsazan (Herston/Brisbane, Australia)

08:48 AM–08:55 AM FC1-5 Understanding benign T-cell infiltration in mycosis fungoides: Malignant clones are not lone P. A. Vieyra-Garcia (Graz/Boston, Austria, MA; USA)


Festsaal Neo-adjuvant Treatment in Skin Cancer Patients

Chairs: H. Pehamberger (Vienna, Austria)H. Gogas (Athens, Greece)

09:00 AM–09:20 AM SY22-1 From adjuvant to neo-adjuvant treatment in skin cancers – time to change the paradigm?J.-J. Grob (Marseille, France)

09:20 AM–09:40 AM SY22-2 Can biomarkers help us to select patients for neo-adjuvant treatment?H. Gogas (Athens, Greece)

09:40 AM–10:00 AM SY22-3 Neoadjuvant treatment in melanoma – a useful strategy?J. Kirkwood (Pittsburgh, USA)

10:00 AM–10:30 AM SY22-4 Surgical strategies to maximize the outcome of neo-adjuvant treatmentA. Testori (Milano, Italy)

36

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Zeremoniensaal Cutaneous Lymphoma II – Therapy Update

Chairs: L. Geskin ( New York, USA)L. Papadavid (Ort, Greece)

09:00 AM–09:15 AM SY23-1 EORTC treatment guidelines 2015F. Trautinger (St. Poelten, Austria)

09:15 AM–09:30 AM SY23-2 Use of alemtuzumab and radiation therapy in CTCLR. A. Clark (Boston, USA)

09:30 AM–09:45 AM SY23-3 Mogamolizumab in CTCLM. Duvic (Houston, USA)

09:45 AM–10:00 AM SY23-4 Treatment update on b-cell lymphomasM. Bagot (Paris, France)

10:00 AM–10:15AM SY23-5 Brentuximab vendotin in CTCLR. Stadler (Minden, Germany)

10:15 AM–10:30 AM SY23-6 Photopheresis in CTCLR. Knobler (Vienna, Austria)


Rittersaal Genetics of Skin Cancer

Chairs: I. Okamoto (Vienna, Austria)B. Bastian (San Francisco, USA)

09:00 AM–09:20 AM SY24-1 Genetics of melanocytic tumors – from benign to malignantB. Bastian (San Francisco, USA)

09:20 AM–09:40 AM SY24-2 Genetic background and UV – how do they cooperate to form skin cancer?N. Hayward (Brisbane, Australia)

09:40 AM–10:00 AM SY24-3 Acquired mutations in melanoma, B-raf and beyondG. McArthur (Brisbane, Australia)

10:00 AM–10:30 AM SY24-4 The role of telomers in skin tumorsR. Kumar (Heidelberg, Germany)

37

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Geheime Ratstube Dermosocopy II Experts

Chairs: W. Stolz (Munich, Germany)C. Rosendahl (Brisbane, Australia)

09:00 AM–09:15 AM SY25-1 Challenging cases W. Stolz (Munich, Germany)

09:15 AM–09:30 AM SY25-2 Twin casesP. Tschandl (Vienna, Austria)

09:30 AM–09:45 AM SY25-3 Nail casesL. Thomas (Lyon, France)

09:45 AM–10:00 AM SY25-4 Non-pigmented casesC. Rosendahl (Brisbane, Australia)

10:00 AM–10:15 AM SY25-5 Unusual casesH. Kittler (Vienna, Austria)

10:15 AM–10:30 AM SY25-6 Challenging high risk patientsS. Puig (Barcelona, Spain)



Festsaal Cutaneous Lymphoma, New Drugs

Chairs: R. Knobler (Vienna, Austria)J. Kirkwood (Pittsburgh, USA)

11:00 AM–11:30 AM PL4-1 New insights in understanding T-cell biology in cutaneous lymphomaR. Clark (Boston, USA)

11:30 AM–12:00 PM PL4-2 New therapies – price vs. value – can we afford it?J. Larkin (London, UK)

12:00 PM–01:15 PM LUNCH BREAK

38

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

Extraordinary insights into an ordinary pathology

Renowned experts present the latest knowledge

Actinic KeratosisEditors: H. Peter Soyer Tarl W. Prow Gregor B.E. Jemec

Skin Barrier FunctionEditor: Tove Agner

Current Problems in Dermatology, Vol. 46Actinic KreatosisVIII + 154 p., 33 fig., 29 in color, 4 tab., 2015CHF 189.00 / EUR 177.00 / USD 222.00 (hard cover or online*)ISBN 978–3–318–02762–4

Current Problems in Dermatology, Vol. 49Skin Barrier FunctionVIII + 164 p., 26 fig., 6 in color, 14 tab., 2016CHF 179.00 / EUR 167.00 / USD 211.00 (hard cover or online*)ISBN 978–3–318–05585–6

Order at: www.karger.com/[email protected]

*online prices for personal customersPrices subject to change, VAT not includedEUR price for eurozone countries,USD price for USA and Latin America only

Current Problems in Dermatology

Editors: P. Itin, G.B.E. Jemec

Vol. 46

Actinic Keratosis

Editors

H.P. SoyerT.W. ProwG.B.E. Jemec

Current Problems in Dermatology

Editors: P. Itin, G.B.E. Jemec

Vol. 49

Skin Barrier Function Editor

T. Agner

KI16406

Available at the

Wisepress booth

Join us in Viennafor the 25 THEADV Congress

25THEADV CONGRESS

EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

28 SEPTEMBER - 2 OCTOBER 2016

AUSTRIA CENTER, VIENNA

VIENNA, AUSTRIA

www.eadvvienna2016.org


12:15 PM–01:15 PM SAT6 BRISTOL-MYERS SQUIBB LUNCH SYMPOSIUM

Zeremoniensaal Immuno Oncology for Melanoma: What’s New?

Chair: C. Hoeller (Vienna, Austria)

12:15 PM–12:20 PM Welcome and introductionC. Hoeller (Vienna, Austria)

12:20 PM–12:30 PM SAT6-1 Melanoma 2016: Recent data and clinical implicationsJ. Weber (New York, USA)

12:30 PM-12:40 PM SAT6-2 The principles and practice of immuno-oncology adverse event managementJ. Larkin (London, UK)

12:40 PM–01:10 PM SAT6-3 Expert insights into patient managementMelanoma case presentations: C. Lebbé (Paris, France) Interactive discussion moderated by: C. Hoeller (Vienna Austria)

01:10 PM–01:15 PM Summary and closeC. Hoeller (Vienna, Austria)


Festsaal How to Overcome Drug Resistance

Chairs: C. Blank (Amsterdam, Netherlands)P. Ascierto (Napels, Italy)

01:30 PM–01:50 PM SY26-1 Update on resistance mechanisms against targeted drugsA. Roesch (Essen, Germany)

01:50 PM–02:10 PM SY26-2 The role of epigenetic adaptations in the escape from BRAF inhibitor therapyK. Smalley (Tampa, USA)

02:10 PM–02:30 PM SY26-3 Resistance against check-point inhibitors – what are the mechanisms?P. Ascierto (Napels, Italy)

02:30 PM–02:50 PM SY26-4 Strategies to overcome drug resistance in melanomaC. Blank (Amsterdam, Netherlands)

41

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Zeremoniensaal Systemic Treatment of Non-Melanoma Skin Cancer

Chairs: A. Stratigos (Athens, Greece)M. Bylaitė-Bučinskienė (Vilnius, Lithuania)

01:30 PM–01:50 PM SY27-1 Systemic drugs to prevent non-melanoma skin cancerA. Stratigos (Athens, Greece)

01:50 PM–02:10 PM SY27-2 Systemic treatment of BCC – current status and future directionsR. Kunstfeld (Vienna, Austria)

02:10 PM–02:30 PM SY27-3 Systemic treatment of metastatic SCC – what’s new?J. Hofbauer (Zuerich, Switzerland)

02:30 PM–02:50 PM SY27-4 Systemic treatment of cutaneous sarcomasR. Gutzmer (Hanover, Germany)


Rittersaal Tumor Immunology

Chairs: T. Tueting (Bonn, Germany)G. Stingl (Vienna, Austria)

01:30 PM–01:50 PM SY28-1 How tumors escape immune surveillanceT. Tueting (Bonn, Austria)

01:50 PM–02:10 PM SY28-2 Killing or control – what defines an effective tumor immune-response?W. Weninger (Sidney, Australia)

02:10 PM–02:30 PM SY28-3 The role of dendritic cells in tumor immunologyG. Stingl (Vienna, Austria)

02:30 PM–02:50 PM SY28-4 Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity G. Markel (Tel Aviv, Israel)

42

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Geheime Ratstube What’s a Drug’s Value?

Chairs: H. Pehamberger (Vienna, Austria)M. Binder (Vienna, Austria)

01:30 PM–01:45 PM SY29-1 How do we define value in cancer careJ. Kirkwood (Pittsburgh, USA)

01:45 PM–02:00 PM SY29-2 The cost impact of modern skin cancer treatments – the European viewM. Binder (Vienna, Austria)

02:00 PM–02:15 PM SY29-3 The cost impact of modern skin cancer treatments – the US viewS. Agarwala (New York, USA)

02:15 PM–02:30 PM SY29-4 Solutions in the adaption to new cancer treatment paradigms C. Zielinski (Vienna, Austria)

02:30 PM–02:50 PM Panel discussion with audience


03:00 PM–04:00 PM SAT7 MSD VIENNA COFFEEHOUSE SYMPOSIUM

Zeremoniensaal Great Debates of Immuno-Oncology Therapies in Advanced Melanoma

Chair: A. Hauschild (Kiel, Germany)

03:00 PM–03:05 PM Welcome and introductionA. Hauschild (Kiel, Germany)

03:05 PM–03:20 PM SAT7-1 Clinical data update on immune checkpoint inhibitorsA. Hauschild (Kiel, Germany)

03:20 PM–03:30 PM SAT7-2 Debate I: Combination immunotherapy vs single-agent immunotherapy: does combination immunotherapy outweigh monotherapy in 1L settings?S. Agarwala (New York, USA)

03:30 PM–03:40 PM SAT7-3 Debate II: Targeted therapy vs immunotherapy: is targeted therapy the most appropriate 1L treatment choice for BRAF-mutated patients?C. Blank (Amsterdam, Netherlands)

43

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


03:40 PM–03:50 PM SAT7-4 Debate III: Novel combinations: should the novel immunotherapy combination regimens be built on the 1L clinical profile established by the ipilimumab + nivolumab combination?J. Weber (New York, USA)

03:50 PM–04:00 PM Q&A Session and close


Festsaal UV-Protection, Vitamin D and Photoaging

Chairs: H. Hoenigsmann (Vienna, Austria)H. Lim (Detroit, USA)

04:05 PM–04:27 PM SY30-1 UV – the good and the bad sidesS. Beissert (Leipzig, Germany)

04:27 PM–04:49 PM SY30-2 Sun protection – how does it work and does it work?H. Hoenigsmann (Vienna, Austria)

04:49 PM–05:11 PM SY30-3 Vitamin-D – what you always wanted to know H. Lim (Detroit, USA)

05:11 PM–05:25 PM SY30-4 Laser therapy of photoagingD. Sarnoff (New York, USA)


Zermoniensaal Melanoma Surgery: Lymph Nodes to Distant

Chairs: M. Ross (Houston, USA)R. Andtbacka (Salt Lake City, USA)

04:05 PM–04:25 PM SY31-1 Lymph node surgery in melanoma patientsJ. Gershenwald (Houston, USA)

04:25 PM–04:45 PM SY31-2 Surgery of distant metastases – when and howA. Testori (Milan, Italy)

04:45 PM–05:05 PM SY31-3 Cutaneous metastases – when to excise and when to treatR. Andtbacka (Salt Lake City, USA)

05:05 PM–05:25 PM SY31-4 How does the role of surgery in melanoma change in the current therapeutic landscapeM. Ross (Houston, USA)

44

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Rittersaal Smart Sequencing or Combination Therapy – in Search for the Best Strategy

Chairs: N. Haass (Queensland, Australia)K. Smalley (Tampa, USA)

04:05 PM–04:25 PM SY32-1 Sequencing in melanoma – which options do we have?C. Blank (Amsterdam, Netherlands)

04:25 PM–04:45 PM SY32-2 How can we make the best use of kinase inhibitors in melanoma?A. Hauschild (Kiel, Germany)

04:45 PM–05:05 PM SY32-3 How can we make the best use of immunotherapy in melanoma?P. Ascierto (Napels, Italy)

05:05 PM–05:25 PM SY32-4 How can we combine new drugs with local treatment strategiesR. Dummer (Zuerich, Switzerland)


Geheime Ratstube Orphan Skin Cancer – Epidemiology, Histopathology, Biology, Therapy

Chairs: R. Loewe (Vienna, Austria)P. Saiag (Paris, France)

04:05 PM–04:20 PM SY33-1 What is “orphan skin cancer”R. Loewe (Vienna, Austria)

04:20 PM–04:40 PM SY33-2 Orphan drugs for orphan skin cancerJ. Becker (Essen, Germany)

04:40 PM – 05:00 PM SY33-3 Surgical therapy of cutaneous sarcomasP. Funovics (Vienna, Austria)

05:00 PM–05:15 PM SY33-4 Dermatofibrosarcoma protuberans – current guidelines P. Saiag (Paris, France)

05:15 PM–05:25 PM SY33-5 Genomic and immune heterogeneity in non-viral merkel cell carcinoma R. Tothill (Melbourne, Australia)

45

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Festsaal Controversies: Sentinel Node and Completion Lymph Node Dissection – Standard of Care?

Chairs: H. Pehamberger (Vienna, Austria)J. Gershenwald (Houston, USA)

05:30 PM–06:00 PM SY34-1 ProM. Ross (Houston, USA)

06:00 PM–06:30 PM SY34-2 ContraC. Garbe (Tuebingen, Germany)

Discussion with the audience


Zeremoniensaal Skin Cancer in Special Patient Subgroups

Chairs: A. Geusau (Vienna, Austria)J. Olah (Szeged, Hungary)

05:30 PM–05:50 PM SY35-1 Epidemiology and prevention of skin cancer in immunosuppressed patients A. Geusau (Vienna, Austria)

05:50 PM–06:10 PM SY35-2 Treatment of skin cancer in immune-supressed patients – different from immunocompetent patients?C. Lebbé (Paris, France)

06:10 PM–06:30 PM SY35-3 Skin cancer in patients previously irradiated – a frequent event? A. Geller (Boston, USA)

46

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Rittersaal Locoregional Therapy of Melanoma Metastases

Chairs: L. Kandolf-Sekulovic (Belgrade, Serbia)S. Agarwala (Bethlehem, USA)

05:30 PM–06:50 PM SY36-1 Therapies for patients with locoregional metastases – What are our current options? R. Dummer (Zuerich, Switzerland)

05:50 PM–06:10 PM SY36-2 Intralesional therapies – what’s around the corner?S. Agarwala (Bethlehem, USA)

06:10 PM–06:30 PM SY36-3 Intralesional and systemic therapies – Which combinations are most promising?R. Andtbacka (Salt Lake City, USA)


Geheime Ratstube Psychodermatooncology

Chair: E. Lehner-Baumgartner (Vienna, Austria)

05:30 PM– 06:00 PM SY37-1 Breaking bad news to cancer patients – the do’s and the dont’sP. Schuetzl (Vienna, Austria)

06:00 PM–06:30 PM SY37-2 Strategies to support our patients beyond Pharmacotherapy – what everyone can doE. Lehner- Baumgartner (Vienna, Austria)

08:00 PM OT3 NETWORKING EVENING

Heuriger Welser

47

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

Immuno-Oncology

62576_EADO_Programme_Advert_v1i_FINAL.indd 1 6/14/16 11:13 AM

Scientific Program Saturday, September 3, 2016

Festsaal Zeremoniensaal Rittersaal Geheime Ratstube

Exhi

bito

n – H

ofbu

rg G

alerie

08:00 AM SY38Side Effects of Systemic Skin Cancer Therapies08:00 AM–09:00 AM

SY39Current Standard

of Imaging Methods for Skin Cancer Patients

08:00 AM–09:00 AM

09:00 AM FC3C. Posch, C. Hoeller

09:00 AM–10:00 AM

FC2A. Steiner,

H. Pehamberger09:00 AM–10:00 AM

10:00 AM Coffee Break10:00 AM–10:30 AM

SY40Predictive Biomarkers

in Melanoma 10:30 AM–11:30 AM

SY41New Methods in Early

Detection of Skin Cancer 10:30 AM–11:30 AM

SY42Brain Metastases

10:30 AM–11:30 AM11:00 AM

PL5Future Targets and

Combinations11:35 AM–12:05 PM

12:00 PM OT4Closing Ceremony

12:05 PM–12:30 PM

49

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Festsaal Side Effects of Systemic Skin Cancer Therapies

Chairs: K. Schindler (Vienna, Austria)C. Loquai (Mainz, Germany)

08:00 AM–08:15 AM SY38-1 Side effects of systemic therapies for NMSCC. Loquai (Mainz, Germany)

08:15 AM–08:30 AM SY38-2 Side effects of targeted therapies for metastatic melanoma (BRAF/MEK)C. Lebbé (Paris, France)

08:30 AM–08:45 AM SY38-3 Side effects of immunotherapies for metastatic melanoma K. Schindler (Vienna, Austria)

08:45 AM–09:00 AM SY38-4 Discussion: How will future combinations impact side effect management?


Zermoniensaal Current Standard of Imaging Methods for Skin Cancer Patients

Chairs: N. Schwenzer (Tuebingen, Germany)M. Mayerhoefer (Vienna, Austria)

08:00 AM–08:15 AM SY39-1 Whole-body staging of melanomaN. Schwenzer (Tuebingen, Germany)

08:15 AM–08:30 AM SY39-2 Treatment response assessment in melanomaM. Mayerhoefer (Vienna, Austria)

08:30 AM–09:00 AM SY39-3 Radiopharmaceuticals for molecular imaging of melanomaM. Mitterhauser (Vienna, Austria)W. Wadsak (Vienna, Austria)

08:00 AM–09:00 AM PW2 POSTERWALK

Marmorsaal/ Antekammer

Non-Melanoma Skin Cancer P100 - P169Cutaneous Lymphoma P170 - P190 Orphan Skin Cancer P191 - P196Skin Cancer in General P197 - P205

50

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Zeremoniensaal A. Steiner (Vienna, Austria)H. Pehamberger (Vienna, Austria)

09:00 AM–09:12 AM FC2-1 Inverse association between atopy and melanoma: a case-control study V. Marasigan (Leuven, Belgium)

09:12 AM–09:24 AM FC2-2 Impact of adjuvant immunotherapy on survival of patients with resected stage III melanoma diagnosed in 2003–2011 in the US S. Jang (Fairfax, VA, USA)

09:24 AM–09:36 AM FC2-3 Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors L. G. Campana (Padova, Italy)

09:36 AM–09:48 AM FC2-4 Sun protection after melanoma diagnosis improves survival C. Mueller, (Vienna, Austria)

09:48 AM–10:00 AM FC2-5 Evaluation of 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of actinic keratosis: a phase III, randomised, vehicle-controlled trial E. Stockfleth (Bochum, Germany)


Festsaal C. Posch (Vienna, Austria)C. Hoeller (Vienna, Austria)

09:00 AM–09:12 AM FC3-1 Can Melanoma treatment be guided by a panel of predictive and prognostic MicroRNA biomarkers? M. Stark (Brisbane, Australia)

09:12 AM–09:24 AM FC3-2 Response patterns to MEK inhibition, but not NRAS mutation status predict the efficacy of combined MEK/CDK4,6 targeting in melanoma C. Posch (Vienna, Austria)

09:24 AM–09:36 AM FC3-3 Incidence, course, and management of toxicities associated with cobimetinib combined with vemurafenib in the cobrim study: an updated analysis B. Dreno (Nantes, France)

09:36 AM–09:48 AM FC3-4 Basal cell carcinoma cancer stem cells promote immune evasion G. Patel (Cardiff, UK)

51

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

v.forghieri

Evidenziato


09:48 AM–10:00 AM FC3-5 Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and long-term follow-up in 24 patients C. Jonak (Vienna, Austria)



Festsaal Predictive Biomarkers in Melanoma

Chairs: J. Becker (Essen, Germany)C. Krepler (Philadelphia, USA)

10:30 AM–10:50 AM SY40-1 What should an ideal biomarker look like?J. Becker (Essen, Germany)

10:50 AM–11:10 AM SY40-2 Biomarkers for targeted therapies beyond B-raf statusD. Schadendorf (Essen, Germany)

11:10 AM–11:30 AM SY40-3 Preclinical evaluation of biomarkers to predict therapeutic responseC. Krepler (Philadelphia, USA)


Zermoniensaal New Methods in Early Detection of Skin Cancer

Chairs: G. Pellacani (Modena, Italy)P. Soyer (Brisbane, Australia)

10:30 AM–10:45 AM SY41-1 Confocal microscopy/multiphoton imaging G. Pellacani (Modena, Italy)

10:45 AM–11:00 AM SY41-2 Electric impedance spectroscopyJ. Malvehy (Barcelona, Spain)

11:00 AM–11:15 AM SY41-3 Total body photographyA. Halpern (New York, USA)

11:15 AM–11:30 AM SY41-4 “Apps” and telemedicine H. P. Soyer (Brisbane, Australia)

52

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER



Rittersaal Brain Metastases

Chairs: M. Preusser (Vienna, Austria)A. Berghoff (Vienna, Austria)

10:30 AM–10:45 AM SY42-1 Biology of brain metastasesA. Berghoff (Vienna, Austria)

10:45 AM–11:00 AM SY42-2 The leptomeningeal microenvironment as protective sanctuary for melanoma cellsI. Fedorenko (Tampa, USA)

11:00 AM–11:15 AM SY42-3 How do the new therapies influence our algorithms for brain metastases? M. Preusser (Vienna, Austria)

11:15 AM–11:30 AM SY42-4 Surgery for brain metastases from cutaneous tumorsJ.-C. Tonn (Munich, Germany)


Festsaal Future Targets and Combinations

Chairs: H. Pehamberger (Vienna, Austria)C. Hoeller (Vienna, Austria)

PL5-1 The future of dermatooncology C. Garbe (Tuebingen, Germany)

12:05 PM–12:30 PM OT4 CLOSING CEREMONY

Festsaal C. Hoeller (Vienna, Austria)

53

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

Scientific Program List of Chairs and Invited Speakers

AAgarwala, Sanjiv SY29; SY36,

SAT7; Chair SY36Alcalay, Joseph SY9Andtbacka, Robert HI SY18; SY31;

SY36; Chair SY31Arenberger, Peter SY1; Chair SY16Argenziano, Giuseppe SY3Ascierto, Paolo SY26; SY32;

Chair SY26

BBagot, Martine SY23Barnhill, Raymond L SY14 Bastian, Boris PL2; SY19; SY24;

Chair SY24Becker, Juergen SY33; SY40; SAT1;

Chair SY40, SAT1Beissert, Stefan SY30Berghoff, Anna SY42; Chair SY42Binder, Michael SY29; Chair SY29Blank, Christian PL3; SY26; SY32,

SAT7; Chair SY26Braathen, Lasse SY17Busam, Klaus J. SY14Bylaitė-Bučinskienė,

Mathilda Chair SY27

CClark, Rachel SY23; PL4

DDreno, Brigitte SY12; FC3;

Chair SY12Dummer, Reinhard SY10, SY12;

SY32; SY36, SAT5; Chair SY16Duvic, Madeleine SY23;

FFargnoli, Maria Concetta SY4;

Chair SY4Fedorenko, Inna SY42 Forsea, Anna Maria SY6; Chair SY6Funovics, Philipp SY33

GGarbe, Claus SY15; SY34; PL5,

SAT3; Chair PL2, SAT3Geller, Allen SY1, SY35 Gershenwald, Jeff SY9; SY15;

SY31; Chair SY34Geskin, Larissa SY20; Chair SY23Geusau, Alexandra SY35;

Chair SY35Gnant, Michael SY15; Chair SY15Gogas, Helen SY22; Chair SY22Grabbe, Stephan SY7; Chair SY7Grob, Jean-Jaque SY8; SY22; SAT2;

SAT3; Chair SY8, SAT2Gutzmer, Ralf SY20; SY27; SAT2;

Chair SY20

HHaass, Nikolas SY11; Chair SY32Hahn, Heidi SY10; Chair SY10Halpern, Allan SY1; SY41;

Chair PL2Handisurya, Alessandra SY13;

Chair SY13Hauschild, Axel SY8; SY32; SAT7;

Chair SY8, SAT7Hayward, Nick SY24; SY2;

Chair SY2; FC1Herlyn, Meenhard SY2; Chair

SY2, FC1

Hoeller, Christoph SY6; SAT4; SAT6; Chair PL1, PL5, SY19, SAT6, FC3, OT4

Hofbauer, Guenther SY13; SY27; Chair SY13

Hofmann-Wellenhof, Rainer SY3 Hoenigsmann, Herbert SY30;

Chair SY30

JJanda, Monika SY1

KKandolf-Sekulovic,

Lidia Chair SY36Kaufmann, Roland SY9; Chair SY9Kirkwood, John SY22; SY29;

Chair PL4Kirnbauer, Reinhard SY2 Kittler, Harald SY3; SY19; SY25;

Chair SY3Knobler, Robert SY23; Chair PL4Krepler, Clemens SY40; Chair SY40Kumar, Rajiv SY24 Kunstfeld, Rainer SY13; SY27;

Chair SY10Kupper, Thomas SY7

LLarkin, James SY16; PL4; SAT2,

SAT5, SAT6; Chair SAT5Lebbé, Céleste SY35; SY38; SAT1;

SAT6; Chair SY21Lehner-Baumgartner, Eva SY37;

Chair SY37Lichtenberger Beate SY2;

Chair SY2Lim, Henry SY30; Chair SY30

54

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

Scientific Program List of Chairs and Invited Speakers

Loewe, Robert SY20; SY33; Chair SY33

Loquai, Carmen SY38; Chair SY38Lorigan, Paul SY20; Chair SY20

MMalvehy, Josep SY3; SY41;

Chair SY4Markel, Gal SY28 Marmol, Veronique Del SY1;

Chair SY1Mayerhoefer, Marius SY39;

Chair SY39McArthur, Grant SY4; SY8; SY24;

Chair PL3Michielin, Olivier SY16; PL3; SAT4 Mihm, Martin C SY14; Chair SY14Mitterhauser, Markus SY39 Mohr, Peter SY6; Chair SY6Mueller, Markus FC2

OOkamoto, Ichiro SY4; Chair SY24Olah, Judith Chair SY35

PPapadavid, Evangelia Chair SY23Paulitschke, Verena SY11;

Chair SY11Pehamberger, Hubert Chair PL1,

SY22, SY29, SY34, PL5, SAT4, FC2

Pellacani, Giovanni SY41; Chair SY41

Petzelbauer, Peter FC1; Chair SY14, FC1

Posch, Christian FC3; Chair FC3

Preusser, Matthias SY42; Chair SY42

Puig, Susanna SY3; SY25

QQualigno, Petro Chair SY5

RRadakovic, Sonja SY17; Chair SY17Robins, Perry Chair SY1 Roesch, Alexander SY 26Roka, Florian SY9; Chair SY9Rosendahl, Cliff SY25; Chair SY25 Ross, Merick SY15; SY31; SY34;

Chair SY31

SSahin, Ugur PL2; SY18; Chair SY18Saiag, Philippe SY33; Chair SY33Sarnoff, Deborah SY30Scarisbrick, Julia SY5; Chair SY5Schadendorf, Dirk SY8, SY12;

SY40; Chair PL3Schindler, Katja SY21; SY38;

Chair SY38Schramek, Daniel SY11;

Chair SY11Schuetzl, Philipp SY37Schuler, Gerold SY18; Chair SY18Schwarz, Thomas SY2Schwenzer, Nina SY39;

Chair SY39Sekulic, Aleksandar PL1; SY10 Sibaud, Vincent SY21; Chair SY21Smalley, Keiran SY26; Chair SY32Sober, Arthur Joel SY14 Sotiriou, Eleni SY17Soyer, H. Peter SY41; Chair SY41

Stadler, Rudolf SY23 Steiner, Andreas Chair FC2Stengel, Fernando SY1 Stingl, Georg SY28; Chair SY28Stockfleth, Eggert SY13; FC2 Stolz, Wilhelm SY25; Chair SY25 Stratigos, Alexander SY10; SY27;

Chair SY27Szeimies, Rolf-Markus SY17;

Chair SY17

TTestori, Alessandro SY22; SY31;

Chair SY15Thomas, Luc SY25Tonn, Joerg-Christian SY42 Trautinger, Franz SY23Tschachler, Erwin SY2 Tschandl, Philipp SY25;

Chair SY19Tueting, Thomas SY28; Chair SY28

VVermeer, Maarten SY5

WWadsak Wolfgang SY39Weber, Jefrey PL1; SY12; SAT6,

SAT7; Chair SY12Weninger, Wolfgang SY7; SY28;

Chair SY7Willemze, Rein SY5 Whittaker, Sean SY5Wolff, Klaus Chair PL1

ZZalaudek, Iris SY3; SAT3; Chair SY3Zielinski, Christoph SY29

55

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

Scientific Program Poster Exhibition

Please see the scientific program on p. 32 and p. 50 for the thematic distribution of the posterwalks..

P001 Cobimetinib plus vemurafenib for unresectable or metastatic melanoma: characteristics and safety data in 376 patients from the French temporary authorization for useDreno B.1, Zehou O.2, Meyer N.3, Mateus C.4, Duval Modeste A.‑B.5, Lebbe C.6

1CHU de Nantes – Hotel Dieu, Department of Dermatology, Nantes, France, 2Hôpital Henri Mondor, Department of Dermatology, Créteil, France, 3IUCT – Oncopole, Department of Dermatology, Toulouse, France, 4Gustave Roussy, Department of Dermatology, Villejuif, France, 5CHU de Rouen – Hôpital Charles Nicolle, Department of Dermatology, Rouen, France, 6Hôpital Saint-Louis, Department of Oncology, Paris, France

P002 Malignant melanoma in Ukraine: Figures and featuresKorovin S.1, Kukushkina M.1, Goulak L.2, Fedorenko Z.2, Palivets A.1, Ostafiichuk V.1, Kovalchuk P.3

1National Cancer Institute, Department of Skin and Soft Tissue Tumors, Kiev, Ukraine, 2National Cancer Institute, Department of Cancer Epidemiology, Kiev, Ukraine, 3National Cancer Institute, Oncologic Orthopedy, Kiev, Ukraine

P003 Eleven years of melanoma patient management – observations and trends from a single-center experience in AustriaPosch C.1, Feichtenschlager V.1, Weihsengruber F.1, Rappersberger K.11The Rudolfstiftung Hospital, Dermatology, Vienna, Austria

P004 Retrospective analysis of clinical and histopathologic characteristics of Malignant Melanoma: an analysis of 24 years’ data from the Department of Dermatology in Cracow, PolandWawrzynkiewicz M.1, Podolec K.1, Szworak M.1, Wojas‑Pelc A.11Jagiellonian University, Collegium Medicum, Department of Dermatology, Cracow, Poland

P005 Ranking of risk factors for cutaneous malignant melanoma in the general population: A systematic review and meta-analysisJoosten V.H.M.J.1, Kelleners‑Smeets N.W.J.1, Dinant G.J.2, Smeets J.G.E.2, Steijlen P.M.1, Nelemans P.J.3

1GROW Research Institute for Oncology and Developmental Biology, Dermatology, Maastricht, Netherlands, 2CAPHRI School for Public Health and Primary Care, Family medicine, Maastricht, Netherlands, 3CAPHRI School for Public Health and Primary Care, Epidemiology, Maastricht, Netherlands

P006 Influence of socioeconomic status on clinical outcomes of malignant melanoma: a cross-sectional study in 746 patientsMolgó M.1, Andino R.1, Navajas L.1, Silva M.J.2, Uribe P.1, Sazunic I.3, González S.2

1Pontificia Universidad Católica de Chile, Dermatology, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Santiago, Chile, 3Universidad de Chile, Santiago, Chile

P007 Clinicopathological characteristics, treatment patterns and outcome of cutaneous melanoma in South-East Europe: first results from the national registry of Serbian Melanoma GroupKandolf Sekulovic L.1, Babovic N.2, Nikolin B.3, Vrbic S.4, Vukanovic T.1, Ostojic N.5, Mijuskovic Z.1, Dinic M.1, Juskic K.2, Jevric M.2, Neric D.2, Todorovic M.4, Tiodorovic D.4, Nikolic D.6, Novakovic M.5, Serbian Melanoma Group1Medical Faculty, Military Medical Academy, Dermatology and Venerology, Belgrade, Serbia, 2Institute of Oncology and Radiology of Serbia, Melanoma and Sarcoma unit, Belgrade, Serbia, 3Institute of oncology of Vojvodina, Melanoma Unit, Novi Sad, Serbia, 4Clinical Center of Nis, Medical Oncology, Nis, Serbia, 5Medical Faculty, Military Medical Academy, Plastic and Reconstructive Surgery, Belgrade, Serbia, 6Clinical Hospital Center ‘Bezanijska Kosa’, Surgical oncology, Belgrade, Serbia

MEL

AN

OM

A

56

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P008 A single-center study on 118 re-excisions and 136 sentinel node biopsies for malignant melanomaAsdahl K.R.1, Stolle L.B.2

1Regionshospitalet Randers, Department of Abdominal Surgery, Randers, Denmark, 2Sygehus Lillebelt, Vejle, Department of Plastic Surgery, Vejle, Denmark

P009 Tumor necrosis factor alpha production is icreased in vitro bearing the R151C variant of MC1R geneCórdoba‑Lanús E.1, Espinoza‑Jiménez A.1, Ramos‑Trujillo E.1, Almeida‑González D.2, Fernández‑de‑Misa R.1,3

1Hospital Universitario Nstra. Sra. de Candelaria, Research Unit, Santa Cruz de Tenerife, Spain, 2Hospital Universitario Nstra. Sra. de Candelaria, Immunology Department, Santa Cruz de Tenerife, Spain, 3Hospital Universitario Nstra. Sra. de Candelaria, Dermatology Department, Santa Cruz de Tenerife, Spain

P010 The HDL receptor controls the metabolic phenotype of human metastatic melanoma cellsKinslechner K.1, Schörghofer D.1, Schütz B.1, Vallianou M.1, Röhrl C.2, Hengstschläger M.1, Moriggl R.3, Stangl H.2, Mikula M.11Medical University of Vienna, Institute of Medical Genetics, Vienna, Austria, 2Medical University of Vienna, Institute of Medical Chemistry, Vienna, Austria, 3University of Veterinary Medicine and Medical University Vienna, Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria

P011 Pharmacological targeting of the IL-6 signalling pathway in human melanoma cells of different stagesWasinger C.1, Svoboda K.1, Hohenegger M.11Medical University of Vienna, Pharmacology, Vienna, Austria

MEL

AN

OM

A

57

SCIE

NTI

FIC

PRO

GR

AM

S. KargerMedical and Scientific PublishersBasel . Freiburg . Paris . London . New York . Chennai . New Delhi . Bangkok . Beijing . Shanghai . Tokyo . Kuala Lumpur . Singapore . Sydney

Wissenstransfer aus

Bestellen Sie gleich hier ein kostenloses Probeheft:

Wissenstransfer aus der Forschung in die PraxisFundiertWissenschaftlichen Beiträge aus internationalen Fachpublikationen in deutscher Übersetzung

KompetentAuswahl und praxisrelevante Kommentierung von Peer-Review-Arbeiten durch namhaften Fachbeirat

PraxisnahÜbersichtlich aufbereitete Informationen für Fachärzte für Haut- & Geschlechtskrankheiten

Neugierig?Unseren Abo-Service erreichen Sie unter:t +49 761 45 207-24, f [email protected]

Besuchen Sie unsere Homepage:www.karger.com/kkd

KKD_Koop_WCCS.indd 1 01.07.2016 11:59:53

WED

THU

FRI

SAT

INDE

XPO

STER


P012 Diverse gene expression changes under targeted inhibitor treatment of primary melanoma cell culturesCheng P.1, Freiberger S.1, Dummer R.1, Levesque M.11University Hospital Zurich, Dermatology, Zurich, Switzerland

P013 Choline transporter-like proteins as a novel molecular target for the therapy of melanomaInazu M.1,2, Yamanaka T.2

1Tokyo Medical University, Institute of Medical Science, Tokyo, Japan, 2Tokyo Medical University, Department of Molecular Preventive Medicine, Tokyo, Japan

P014 CXCL5 alters metastatic patterns of malignant melanomaForsthuber A.1, Lipp K.1, Gröger M.2, Loewe R.1,3

1Medical University of Vienna, Skin & Endothelium Research Division SERD, Department of Dermatology, Vienna, Austria, 2Medical University of Vienna, Core Facility Imaging, Vienna, Austria, 3Medical University of Vienna, Division of General Dermatology and Dermatooncology, Department of Dermatology, Vienna, Austria

P015 Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesionsRocha L.1,2, Guitera P.1,3, Khoury R.1, Avramidis M.3, Lo S.4, Menzies S.11Sydney Melanoma Diagnostic Centre, Dermatology, Sydney, Australia, 2São Paulo University, Dermatology Department of Hospital das Clínicas, São Paulo, Brazil, 3Melanoma Institute Australia, Dermatology, Sydney, Australia, 4Melanoma Institute Australia, Statistics, Sydney, Australia

P016 RRE inhibit melanogenesis in B16F0 melanoma cells through MAP kinase pathwayChien T.‑Y.1, Wang H.‑W.1, Liao H.‑F.1, Lin I.‑H.1, Lo Y.‑F.1, Chiang H.‑M.1, Wen K.‑C.1, Takashi Y.2

1China Medical University, Cosmeceutics, Taichung, Taiwan, Republic of China, 2National University Corporation Kitami Institute of Technology, Hokkaido, Japan

P017 PTEN: a novel target for vitamin D in the fight against melanomaShariev A.1, Painter N.1, Mason R.2, Dixon K.11University of Sydney, Discipline of Anatomy and Histology, Bosch Institute, School of Medical Sciences, Sydney Medical School, Sydney, Australia, 2Discipline of Physiology, Bosch Institute, University of Sydney, School of Medical Sciences, Sydney Medical School, Sydney, Australia

P018 Cost-effectiveness of population-based skin cancer screeningHoorens I.1, Pil L.2, Vossaert K.3, Annemans L.2, Brochez L.11University Hospital Ghent, Dermatology, Ghent, Belgium, 2University Hospital Ghent, Public Health, Ghent, Belgium, 3Private Practice, Maldegem, Dermatology, Maldegem, Belgium

P019 Effect and mechanisms of MGE in melanoma cellsLiu Y.‑J.1, Wang H.‑W.1, Chen P.‑W.1, Lu X.‑Y.1, Hsu L.‑Y.1, Takashi Y.2, Wen K.‑C.1, Chiang H.‑M.11China Medical University, Department of Cosmeceutics, Taichung, Taiwan, Republic of China, 2National University Corporation Kitami Institute of Technology, Hokkaido, Japan

P020 Primary cutaneous malignant melanoma: not a rarity in Asian skinSaikia U.N.1, Khullar G.2, De D.2, Handa S.2, Radotra B.D.11Post Graduate Institute of Medical Education and Research, Histopathology, Chandigarh, India, 2Post Graduate Institute of Medical Education and Research, Dermatology, Chandigarh, India

MEL

AN

OM

A

58

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P021 Evaluation of nodal cellular morphology and pigmentation as prognostic factors in melanoma patients with positive sentinel nodesBertolli E.1, Macedo M.P.2, Molina A.S.1, Damascena A.S.3, Pinto C.A.L.2, Duprat Neto J.P.11AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São Paulo, Brazil, 3AC Camargo Cancer Center, International Center for Research, São Paulo, Brazil

P022 Micromorphometric evaluation of sentinel nodes in melanoma patients: The value of metastatic size, localization, and depthBertolli E.1, Macedo M.P.2, Molina A.S.1, Damascena A.S.3, Pinto C.A.L.2, Duprat Neto J.P.11AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São Paulo, Brazil, 3AC Camargo Cancer Center, International Center for Research, São Paulo, Brazil

P023 A retrospective study of the pathological prognostic indicators of small diameter melanomaColtart H.1, Dawar B.1, Darling M.2, Moyes C.3, Gupta G.4

1University of Glasgow, Glasgow, United Kingdom, 2Queen Elizabeth University Hospital, Dermatology, Glasgow, United Kingdom, 3Queen Elizabeth University Hospital, Pathology, Glasgow, United Kingdom, 4NHS Lanarkshire, Dermatology, Glasgow, United Kingdom

P024 Spitz tumors and other histopathological pitfalls: Diagnosis with Dermato fluoroscopyGiering H.‑G.1, Buder S.2, Stankovic G.1, Leupold D.11Magnosco GmbH, Berlin, Germany, 2Vivantes-Klinikum Berlin Region Süd, Berlin, Germany

P025 Histological features of metastatic melanoma under targeted therapies - A report of 3 casesGoldman‑Lévy G.1,3, Laurent‑Bellue A.1, Plantier F.1, Just P.‑A.1,3, Rouquette A.1, Beuvon F.1, Dallot A.1, Aractingi S.2,3, Carlotti A.1, Kramkimel N.2, Avril M.‑F.2,3, Terris B.1,3

1Hôpital Cochin, Dept. of Pathology, Paris, France, 2Hôpital Cochin, Dept. of Dermatology, APHP Groupe Hospitalier Paris Centre, Paris, France, 3Université Paris Descartes, Faculty of Medecine Paris Descartes, Paris, France

P026 New in complex non-invasive diagnosis of melanomaKurdina M.1, Makarenko L.2, Lebedeva A.3, Kurdina E.11GK ‘MEDSI’, Dermatology, Moscow, Russian Federation, 2Research Center of Russian Railways, Dermatology, Moscow, Russian Federation, 3International Medical Leech Centre, Dermatology, Udelnaya pos, Russian Federation

P028 Two-photon-excitation melanin fluorescence measurement for melanoma detectionNouri N.1, Spänkuch I.1, Lomberg D.1, Tampouri I.1, Forschner A.1, Garbe C.11Eberhard Karl University, University Department of Oncology, Tübingen, Germany

P029 Pre-operative imaging for newly diagnosed primary melanoma: Stage 0 – stage IICCallaghan D.1, Kakar R.2, Jang S.3, Venna S.3

1Boston University, Dermatology, Boston, United States, 2University of Oklahoma, Dermatology, Oklahoma City, United States, 3Inova Schar Cancer Institute, Fairfax, United States

P030 Melapred: first susceptibility test to sporadic melanoma in daily dermatological practiceSoufir N.1,2, Benfodda M.1,2, Gazal S.3, Descamps V.4, Madjlessi N.5, Lebbe C.6, Basset‑Seguin N.6, Archimbaud A.6, Opletalova K.4, Vuong V.4, Nicaise‑Bergere C.7, Massart‑Manil S.7, Machuel B.8, Saiag P.9, Merrouche Y.10, Bensussan A.2, Nagore E.11, Kumar R.12, Grange F.13

1Bichat Hospital, Genetic, Paris, France, 2Centre de recherche sur la peau, U976, Paris, France, 3Bichat Hospital, Biostatistic, Paris, France, 4Bichat Hospital, Dermatology, Paris, France, 5Private Practice, Dermatology, Paris, France, 6Saint Louis Hospital, Dermatology, Paris, France, 7Private General Practice, Reims, France, 8Private General Practice, Rilly La Montagne, France, 9Ambroise Pare Hospital, Dermatology, Boulogne Billancourt, France, 10Jean Godinot Institute, Reims, France, 11Instituto di Oncologia, Dermatology, Valencia, Spain, 12German Cancer Research Center, Division of Molecular Genetic Epidemiology, Heidelberg, Germany, 13CHU de Reims, Dermatology, Reims, France

MEL

AN

OM

A

59

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P031 MELADIAG: a panel of DNA biomarkers dedicated to melanoma diagnosisBenfodda M.1,2, Marinho E.3, Kumar R.4, Lamoril J.1, Beaudoux O.5, Reocreux M.1, Grange F.6, Dechamps L.3, Bensussan A.2, Merrouche Y.7, Soufir N.1,2

1Bichat Hospital, Genetic, Paris, France, 2Centre de recherche sur la peau, U976, Paris, France, 3Bichat Hospital, Pathological Anatomy, Paris, France, 4German Cancer Research Center, Division of Molecular Genetic Epidemiology, Heidelberg, Germany, 5Jean Godinot Institute, Dermatology, Reims, France, 6CHU de Reims, Dermatology, Reims, France, 7Jean Godinot Institute, Reims, France

P032 Epidemiological pattern of patients with melanoma in Minsk region (Belarus) using digital dermoscopy (2013–2014)Prakoshyn A.1, Zhukavets A.2, Lud N.3

1Vitebsk Regional Oncology Center, Vitebsk State Medical University, General Oncology, Vitebsk, Belarus, 2N.N. Alexandrov National Cancer Centre of Belarus, Minsk Region, Belarus, 3Vitebsk State Medical University, Vitebsk, Belarus

P033 Spectrophotometric method of intradermal test for pigmented skin lesions diagnosisSokolova A.1, Malishevskaya N.2

1Ural Medical Clinic, Yekaterinburg, Russian Federation, 2Ural Research Institute of Dermatology, Venerology and Immunopathology, Yekaterinburg, Russian Federation

P034 The deceiving faces of melanomaRados J.1, Loncaric D.1, Bradamante M.1, Ilic I.2, Marinovic B.11UHC Zagreb and School of Medicine, University of Zagreb, Department of Dermatovenereology, Zagreb, Croatia, 2UHC Zagreb and School of Medicine, University of Zagreb, Department of Pathology, Zagreb, Croatia

P035 Mobile teledermoscopy. A useful tool to evaluate suspicious lesions. Pilot project in Rosario, ArgentinaAlonso C.1, Salerni G.1, Fernandez Bussy R.11Hospital Provincial del Centenario, Dermatology, Rosario, Argentina

P036 Dermoscopic features of scalp melanomaOganesian M.1, Smirnova I.1, Dobrovolskiy E.2, Getman A.3

1Saint-Petersburg State University, Medical Faculty, Department of Infectious Diseases, Epidemiology and Dermatovenereology, Saint-Petersburg, Russian Federation, 2Svedlovsk Regional Dermatovenerologic Dispensary, Branch No.2, Nizhny Tagil, Russian Federation, 3Medical Center ‘Neo Clinic’, Department of Oncology, Tyumen, Russian Federation

P037 Decreasing dermoscopy score of pigmented lesions following treatment with mild immunostimulatory treatmentRussu L.1, Sprincenatu C.1, Russu M.2, Russu E.3

1Bioderm Medical Center, Bucharest, Romania, 2Bio Medica, Bucharest, Romania, 3Bioderm Laser Clinic, Bucharest, Romania

P038 Future of care for patients at high risk for melanoma: from multimode, hyperspectral dermoscopy to self-imaging with smartphoneFarkas D.L.1,2, Vasefi F.1, MacKinnon N.B.1, Durkin A.J.3, Kelly K.M.3

1Spectral Molecular Imaging Inc., Beverly Hills, United States, 2University of Southern California, Los Angeles, United States, 3University of California, Irvine, United States

P039 Small diameter melanomas – two case reportsŠtulhofer Buzina D.1, Čeović R.1, Bradamante M.1, Lončarić D.1, Jurakić Tončić R.11University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia

MEL

AN

OM

A

60

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P040 Sudden eruption of multiple Meyerson naeviJerkovic Gulin S.1, Rados J.2, Loncaric D.2, Ceovic R.2,3, Marinovic B.2,3

1General Hospital Sibenik, Infectious Diseases and Dermatology and Venereology, Sibenik, Croatia, 2University Hospital Center Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 3University of Zagreb School of Medicine, Zagreb, Croatia

P041 Total number of common and atypical melanocytic nevi in patients with melanoma in TurkeySallahoglu K.1, Cengiz F.P.1, Emiroglu N.1, Erdogan Güven Z.2, Onsun N.11Bezmialem Vakif University, Istanbul, Turkey, 2University of Kragujevac, Kragujevac, Serbia

P042 Nevus lipomatosus cutaneus superficialis of the scalp in association with melanocytic nevusTsekova Traykovich N.1, Grozdev I.1, Balabanova M.1, Miteva L.11Medical University Sofia, Dermatology and venereology, Sofia, Bulgaria

P043 Characteristics of Lymphangiogenesis in MelanomaWenzina J.1, Puujalka E.1, Petzelbauer P.11Medical University of Vienna, Skin & Endothelium Research Division (SERD), Vienna, Austria

P044 Generation of an affinity purified antibody for the detection of metastatic melanomaSchütz B.1, Koppensteiner A.2, Hundsberger H.2, Missbichler A.3,4, Mikula M.11Medical University of Vienna, Medical Genetics, Vienna, Austria, 2IMC University of Applied Sciences Krems, Department Life Sciences, Krems, Austria, 3Sciotec Diagnostic Technologies GmbH, Tulln, Austria, 4FIANOSTICS GmbH, Wr. Neustadt, Austria

P045 Single-center “real life experience” with pembrolizumab (PEMBRO) in advanced melanoma patients and analysis of baseline factors that correlate with outcomeJansen Y.1, Schreuer M.1, Neyns B.11UZ Brussel, Oncologie, Jette, Belgium

P046 Expression of MAGL as a tumor progression marker in malignant melanomaBaba Y.1, Tanese K.1, Mori M.1, Funakoshi T.1, Amagai M.11Keio University School of Medicine, Department of Dermatology, Shinjuku, Japan

P047 Genetic polymorphisms in toll like receptors genes as prognostic biomarkers in melanoma patientsSupic G.1, Ostojic N.2, Kandolf Sekulovic L.3, Vukanovic T.3, Rajovic M.2, Mijuskovic Z.3, Magic Z.11Medical Faculty, Military Medical Academy, Institute for Medical Research, Belgrade, Serbia, 2Medical Faculty, Military Medical Academy, Plastic and Reconstructive Surgery, Belgrade, Serbia, 3Medical Faculty, Military Medical Academy, Dermatology and Venerology, Belgrade, Serbia

P048 Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib combined with vemurafenib in BRAFV600-mutant melanomaDaud A.1, Pavlick A.C.2, Ribas A.3, Gonzalez R.4, Lewis K.D.4, Hamid O.5, Gajewski T.F.6, Puzanov I.7, Hsu J.J.8, Rooney I.8, Choong N.W.8, Mcarthur G.A.9,10

1University of California, San Francisco School of Medicine, Medicine (Hematology/Oncology), San Francisco, United States, 2New York University Medical Center, New York, United States, 3Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angles, United States, 4University of Colorado Comprehensive Cancer Center, Aurora, United States, 5The Angeles Clinic and Research Institute, Los Angeles, United States, 6The University of Chicago, Chicago, United States, 7Vanderbilt-Ingram Cancer Center, Nashville, United States, 8Genentech, Inc., South San Francisco, United States, 9Peter MacCallum Cancer Centre, East Melbourne, Australia, 10University of Melbourne, Parkville, Australia

MEL

AN

OM

A

61

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P049 Timing of onset and resolution of adverse events in patients with unresectable stage IIIB–IVM1a melanoma treated with talimogene laherparepvec (T-VEC) in OPTiMAndtbacka R.1, Kaufman H.2, Harrington K.3, Middleton M.4, Melcher A.3, Ottensmeier C.5, Safaei R.6, Downey G.7, He P.8, Collichio F.9

1Huntsman Cancer Institute, University of Utah, Salt Lake City, United States, 2Rutgers Cancer Institute of New Jersey, New Brunswick, United States, 3The Institute of Cancer Research/The Royal Marsden Hospital NIHR Biomedical Research Centre, London, United Kingdom, 4Oxford NIHR Biomedical Research Centre, Department of Oncology, Oxford, United Kingdom, 5University of Southampton and University Hospital Southampton NHS Foundation Trust, Cancer Sciences Unit, Southampton, United Kingdom, 6Amgen (Europe) GmBH, Zug, Switzerland, 7Amgen Ltd., Cambridge, United Kingdom, 8Amgen Inc., Thousand Oaks, United States, 9The University of North Carolina, Chapel Hill, United States

P050 Impact of endoplasmic reticulum stress on melanoma malignancyEigner K.1, Filik Y.1, Klambauer G.2, Swoboda A.3, Moriggl R.3, Stangl H.1, Mikula M.1, Röhrl C.11Medical University of Vienna, Vienna, Austria, 2Johannes Kepler University, Linz, Austria, 3Ludwig Boltzmann Institute Cancer Research, Vienna, Austria

P051 The value of PET/CT patterns in response prediction of metastasized melanoma treated with ipilimumabUrosevic‑Maiwald M.1, Goldinger S.M.1, Sommerauer M.2, Dummer R.1, Schaefer N.G.2,3

1University Hospital Zurich, Dermatology, Zurich, Switzerland, 2University Hospital Zurich, Nuclear Medicine, Zurich, Switzerland, 3Lausanne University Hospital, Nuclear Medicine and Molecular Imaging, Lausanne, Switzerland

P054 Electrochemotherapy in the treatment of metastatic malignant melanoma: Results from the InspECT registryKunte C.1,2, Letule V.2, Gehl J.3, Dahlstroem K.4, Curatolo P.5, Rotunno R.5, Muir T.6, Occhini A.7, Bertino G.7, Powell B.8, Saxinger W.9, Lechner G.9, Liew S.H.10, Pritchard Jones R.10, Rutkowski P.11, Zdzienicki M.11, Mowatt D.12, Sykes A.J.13, Orlando A.14, Mitsala G.14, Rossi C.R.15,16, Campana L.15,16, Brizio M.17, de Terlizzi F.18, Quaglino P.17, Odili J.8

1Artemed Fachklinik, Department of Dermatologic Surgery and Dermatology, Munich, Germany, 2Ludwig-Maximilian University Munich, Department of Dermatology and Allergology, Munich, Germany, 3Copenhagen University Hospital Herlev, Center for Experimental Drug and Gene Electrotransfer, Department of Oncology, Herlev, Denmark, 4Copenhagen University Hospital Herlev, Department of Plastic Surgery, Herlev, Denmark, 5University of Rome “La Sapienza”, Department of Dermatology and Plastic Surgery, Rome, Italy, 6James Cook University Hospital, Department of Reconstructive Plastic Surgery, Middlesbrough, United Kingdom, 7University of Pavia, Department of Otolaryngology Head & Neck Surgery, Pavia, Italy, 8St. Georges Hospital, Department of Plastic Surgery, London, United Kingdom, 9Klinikum Wels-Grieskirchen, Department of Dermatology, Wels, Austria, 10Whiston Hospital, Department of Plastic Surgery, Prescot, United Kingdom, 11Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland, 12Christie Hospital, NHS Foundation Trust, Plastic Surgery Department, Manchester, United Kingdom, 13Christie Hospital, NHS Foundation Trust, Department of Clinical Oncology, Manchester, United Kingdom, 14Southmead Hospital, North Bristol NHS Trust, Department of Plastic and Reconstructive Surgery, Bristol, United Kingdom, 15University of Padova, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy, 16University of Padova, Department of Surgery Oncology and Gastroenterology, Padova, Italy, 17University of Torino, Department of Medical Sciences, Dermatologic Clinic, Torino, Italy, 18IGEA, Scientific & Medical Department, Carpi, Italy

P055 An exploratory study investigating the metabolic activity and local cytokine profile in melanoma patients treated with pazopanib and paclitaxelThurneysen S.1, Cheng P.F.1, Nagel H.W.2, Kunz M.1, Jaberg‑Bentele N.1, Naegeli M.1, Guenova‑Hötzenecker E.1, Goldinger S.1, Mangana J.1, Levesque M.P.1, Dummer R.11University Hospital Zurich, Dermatology, Zuerich, Switzerland, 2University Hospital Zurich, Nuclear Medicine, Zuerich, Switzerland

MEL

AN

OM

A

62

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

v.forghieri

Evidenziato


P056 Sentinel lymph node biopsy for lower extremity melanoma with dual-basin uptake on lymphoscintigraphySon J.1, Kim J.‑H.1, Hur N.1, Park I.1, Choe J.‑H.1, Kim J.S.11Samsung Medical Center,Sungkyunkwan University School of Medicine, Department of Surgery, Seoul, Korea, Republic of

P057 Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 studyHauschild A.1, Chapman P.B.2, Robert C.3, Larkin J.4, Haanen J.B.5, Ribas A.6, Hogg D.7, Hamid O.8, Ascierto P.A.9, Testori A.10, Lorigan P.11, Dummer R.12, Sosman J.A.13, Flaherty K.T.14, Wongchenko M.J.15, Yan Y.15, Chang I.15, Coleman S.15, Caro I.15, Mcarthur G.A.16,17

1University Hospital Schleswig-Holstein, Kiel, Germany, 2Memorial Sloan Kettering Cancer Center, New York, United States, 3Institut Gustave Roussy, Paris, France, 4Royal Marsden NHS Foundation Trust, London, United Kingdom, 5The Netherlands Cancer Institute, Amsterdam, Netherlands, 6Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, United States, 7Princess Margaret Hospital and University Health Network, Toronto, Canada, 8The Angeles Clinic and Research Institute, Los Angeles, United States, 9Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy, 10Istituto Europeo di Oncologia, Milan, Italy, 11University of Manchester, Manchester, United Kingdom, 12University of Zurich, Zurich, Switzerland, 13Vanderbilt University School of Medicine, Nashville, United States, 14Massachusetts General Hospital, Boston, United States, 15Genentech, Inc., South San Francisco, United States, 16Peter MacCallum Cancer Centre, East Melbourne, Australia, 17University of Melbourne, Parkville, Australia

P058 TERT promoter mutations in patients with BRAFV600-mutated melanoma treated with vemurafenib or cobimetinib combined with vemurafenibWongchenko M.J.1, Larkin J.2, Mcarthur G.A.3,4, Ribas A.5, Dréno B.6, Chapman P.B.7, Maio M.8, Garbe C.9, Robert C.10, Lu W.1, Diala I.1, Darbonne W.C.1, Chang I.1, Hsu J.J.1, Caro I.1, Rooney I.1, Ascierto P.A.11, Yan Y.11Genentech, Inc., South San Francisco, United States, 2Royal Marsden NHS Foundation Trust, London, United Kingdom, 3Peter MacCallum Cancer Centre, East Melbourne, Australia, 4University of Melbourne, Melbourne, Australia, 5Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, United States, 6Nantes University, Nantes, France, 7Memorial Sloan Kettering Cancer Center, New York, United States, 8University Hospital of Siena, Siena, Italy, 9University of Tuebingen, Tuebingen, Germany, 10Institut Gustave Roussy, Villejuif, France, 11Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

P060 The Sentinel Lymph Node Biopsy in thin melanoma (Breslow ≤ 0.75mm and 0.76–1.0mm)Kechagias G.1, Marra A.1, Karonidis A.1, Kyriopoulos E.1, Tsoutsos D.11General Hospital ‘G. Gennimatas’, Plastic Surgery, Athens, Greece

P061 Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandMangana J.1, Amann V.C.1, Goldinger S.M.1, Kaufmann C.2, Frauchiger A.L.1, Cheng P.1, Stögner V.3, Held U.4, Von Moos R.5, Romano E.6, Michielin O.7, Braun R.1, Levesque M.P.1, Dummer R.11University Hospital Zurich, Department of Dermatology, Zurich, Switzerland, 2University of Zurich, Zurich, Switzerland, 3Medical University of Vienna, Vienna, Austria, 4Horten Centre for Patient Oriented Research and Knowledge Transfer, Zurich, Switzerland, 5Cantonal Hospital Graubünden, Chur, Switzerland, 6Department of Oncology, Service of Medical Oncology, Research Unit 932, Institut Curie, Paris, France, 7University of Lausanne and Centre Hospitalier Universitaire Vaudois (CHUV), Department of Oncology, Lausanne, Switzerland

P062 Clinical and demographic characteristics of patients (pts) treated with vemurafenib in real-world settingSadetsky N.1, Corvino F.2, Surinach A.2, Goodman G.11Genentech, Inc., South San Francisco, United States, 2Genesis Research LLC, Hoboken, United States

MEL

AN

OM

A

63

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P063 Trial in progress: Clinical trial of nivolumab combined with ipilimumab followed by nivolumab monotherapy as first-line therapy of patients with stage III (unresectable) or stage IV melanoma: CheckMate 401Dummer R.1, Gutzmer R.2, Corrie P.3, Millward M.4, Murzhenko A.5, Maio M.6

1UniversitätsSpital Zürich, Zurich, Switzerland, 2Medizinische Hochschule Hannover, Hannover, Germany, 3Addenbrooke’s Hospital, Cambridge, United Kingdom, 4Sir Charles Gairdner Hospital, Nedlands, Australia, 5Bristol-Myers Squibb, Princeton, United States, 6University Hospital of Siena, Siena, Italy

P064 Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma: A phase I, open-label, single-arm studySchadendorf D.1, Michielin O.2,3, Nägeli M.4, Goldinger S.M.4, Campigotto F.5, Kriemler‑Krahn U.6, Schmid H.A.6, Pedroncelli A.M.6, Micaletto S.4, Dummer R.4

1University Hospital Essen, Department of Dermatology, Essen, Germany, 2Lausanne University Hospital (CHUV), Multidisciplinary Oncology Center, Lausanne, Switzerland, 3Swiss Institute of Bioinformatics (SIB), Lausanne, Switzerland, 4University Hospital Zürich, Department of Dermatology, Zürich, Switzerland, 5Novartis Pharmaceuticals Corporation, East Hanover, United States, 6Novartis Pharmaceuticals AG, Basel, Switzerland

P065 Photodynamic therapy of dermatological melanoma using transoethosomes drug delivery systemRady M.1, Afifi N.2, Gomaa I.3, Abdel Kader M.4

1Faculty of Pharmacy and Biotechnology, German University in Cairo, Pharmaceutical Technology, Cairo, Egypt, 2Faculty of Pharmacy and Biotechnology, German University in Cairo, and Faculty of Pharmacy – Cairo University, Pharmaceutical Technology, Cairo, Egypt, 3Faculty of Pharmacy and Biotechnology, German University in Cairo, Biotechnology, Cairo, Egypt, 4German University in Cairo, Cairo, Egypt

P066 Complete lymph node dissection could not be beneficial in sentinel lymph node positive patientsHur N.1, Kim J.1, Son J.2

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Endocrine Surgery, Seoul, Korea, Republic of, 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Surgery, Seoul, Korea, Republic of

P067 Novel insights into hyperthermia s therapeutic effectiveness in treating malignant melanomaMantso T.1, Vasiliadis S.2, Lampri E.3, Anestopoulos I.2, Botaitis S.4, Goussetis G.5, Chlichlia K.2, Pappa A.2, Panagiotidis M.11Heriot Watt University, School of Life Sciences, Edinburgh, United Kingdom, 2Democritus University of Thrace, Department of Molecular Biology & Genetics, Alexandroupolis, Greece, 3University of Ioannina, Department of Pathology, Medical School, Ioannina, Greece, 4Democritus University of Thrace, Second Department of Surgery, Medical School, Alexandroupolis, Greece, 5Heriot Watt University, School of Engineering & Physical Sciences, Edinburgh, United Kingdom

P068 Radiation therapy in melanoma patients with poor clinical characteristics – a collaborative experience with 107 patientsPosch C.1, Steffal C.2, Haider A.1, Flechl B.2,3, Kann T.2, Weihsengruber F.1, Schratter‑Sehn A.U.2

1The Rudolfstiftung Hospital, Dermatology, Vienna, Austria, 2Kaiser- Franz-Josef Hospital, Institute for Radio-oncology, Vienna, Austria, 3Medaustron, Wr. Neustadt, Austria

P069 Immunotherapy with human iPS-cell derived myeloid cell lines producing Type I interferons against metastatic melanomaMiyashita A.1, Fukushima S.1, Nakahara S.1, Kubo Y.1, Tokuzumi A.1, Senju S.2, Nishimura Y.2, Jinnin M.1, Ihn H.11Kumamoto University, Dermatology and Plastic Surgery, Kumamoto, Japan, 2Kumamoto University, Immunogenetics, Kumamoto, Japan

MEL

AN

OM

A

64

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P070 Treatment of primary skin melanoma with traditional medicine methodsStroka Koka A.1, Stroka L.11ALMS Medical Care, Tirana, Albania

P071 CONVERCE: Evaluation of cobimetinib and vemurafenib combination treatment in patients with brain metastases from BRAFV600 mutated melanomaLesimple T.1, Campillo‑Gimenez B.1, Leccia M.T.2, Mahmoudi A.3, Lebbe C.4, French Dermatology Society1Centre Eugene Marquis, Rennes, France, 2CHU de Grenoble, Grenoble, France, 3Laboratoires Roche, Boulogne Billancourt, France, 4Hôpital Saint-Louis, Paris, France

P072 Early follow-up of vemurafenib+cobimetinib combination therapy in 13 melanoma patients: a Roche pre-approval access program in HungaryGorka E.1, Czirbesz K.1, Imredi E.1, Panczel G.1, Liszkay G.11National Institute of Oncology, Dermatooncology, Budapest, Hungary

P073 Correlation between vitiligo and clinical outcome in patient with advanced melanoma treated with nivolumabNakamura Y.1, Asami Y.1, Tanaka R.2, Teramoto Y.1, Imamura T.1, Sato S.1, Maruyama H.2, Fujisawa Y.2, Fujimoto M.2, Yamamoto A.11Saitama Medical University International Medical Center, Skin Oncology/Dermatology, Hidaka, Japan, 2University of Tsukuba, Dermatology, Tsukuba, Japan

P074 Follow-up atypical melanocytic lesions with Dermato fluoroscopy: Rapid malignant degeneration, stable state or repairScholz M.1, Leupold D.2, Szyc L.2, Stankovic G.2, Pfeifer L.1, Buder S.3, Giering H.‑G.2

1LTB Lasertechnik Berlin GmbH, Berlin, Germany, 2Magnosco GmbH, Berlin, Germany, 3Vivantes Klinikum Berlin Region Süd, Klinik für Dermatologie und Venerologie, Berlin, Germany

P075 Multiple primary melanomas in a 59-years-old patient with xeroderma pigmentosum, with a follow-up of 36 yearsAbeldaño A.1, Arias M.1, Gonzalez A.2, Cinque Z.1, Romero Costa L.1, Benedetti A.1, Maskin M.1, Rothlin A.11Hospital Gral. de Agudos Dr. Cosme Argerich. Universidad de Buenos Aires, Buenos Aires, Argentina, 2Hospital Dr. Angel Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina

P076 Lack of vitamin D toxicity in a longterm high dose vitamin D supplementation study for cutaneous malignant melanoma (CMM)De Smedt J.1, Van Kelst S.1, Van Eecke L.1, Vanderschueren D.2, Pauwels S.3, Billen J.3, Vandenberghe K.4, Nikkels A.5, Garmyn M.11Catholic University Leuven, Dermatology, Leuven, Belgium, 2Catholic University Leuven, Endocrinology, Leuven, Belgium, 3Catholic University Leuven, Laboratory medicine, Leuven, Belgium, 4Catholic University Leuven, Cardiology, Leuven, Belgium, 5Centre Hospitalier Universitaire de Liège, Dermatology, Liege, Belgium

P077 Significance of CT scans in melanoma surveillance – 10 year retrospective, single center experienceLengyel Z.1, Pozsgai M.1, Németh K.1, Gyulai R.11University of Pécs, Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary

MEL

AN

OM

A

65

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P078 The effect of psycho-educational interventions on health outcomes in individuals at increased risk for melanoma: A systematic review of randomized controlled trialsCoroiu A.1, Moran C.2, Rice D.3, Kinglsland E.4, Thombs B.5,6, Korner A.11McGill University, Educational and Counselling Psychology, Montreal, Canada, 2University of Ottawa, Psychology, Ottawa, Canada, 3McGill University, Psychology, Montreal, Canada, 4McGill University, Humanities and Social Sciences Library, Montreal, Canada, 5McGill University, Psychiatry, Montreal, Canada, 6Jewish General Hospital, Montreal, Canada

P079 Maligant melanoma masquerading as benign dermatosesDetrixhe A.1, Lebas E.1, Nikkels A.2

1University of Liège, Dept of Dermatology, Liège, Belgium, 2CHU du Sart Tilman, Dermatology, Liège, Belgium

P080 Successful management of Lower eyelid melanomaKim J.M.1, Rhie J.W.11Seoul St. Mary’s Hospital, Plastic surgery, Seocho-gu, Korea,

P081 Vitiligo and tumoral melanosis: signs of metastasis in a melanoma patientTan W.P.1, Yeo B.1, Chia H.Y.1, Cheng S.1, Heng Y.K.1, Lee J.11National Skin Centre, Singapore, Singapore

P082 14 months progression free survival with Dabrafenib therapy without previous stereotactic radiotherapy in a patient with Metastatic MelanomaImrédi E.1, Czirbesz K.1, Gorka E.1, Pánczél G.1, Lőrincz L.1, Liszkay G.11National Institute of Oncology, Department of Dermatology, Budapest, Hungary

P083 Malignant melanoma of unknown primary origin treated with negative pressure wound therapy and punch graftKim M.S.1, Lee Y.S.1, Na C.H.1, Shin B.S.11Chosun University Medical School, Department of Dermatology, Gwang-ju, Korea, Republic of

P084 Conservative surgery for subungual in situ melanoma using Matriderm®Campagnari M.1, Carneiro H.A.2, Jafelicci A.S.2, Gomes E.E.1, Bertolli E.1, Duprat Neto J.P.11AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Surgical Oncology Residence, São Paulo, Brazil

P085 Invasive malignant melanoma accompanied by leukodermaPark B.J.1, Cheon D.U.1, Oh E.H.1, Shin J.M.1, Kim E.J.1, Ko J.Y.1, Ro Y.S.1, Kim J.E.11Hanyang University College of Medicine, Dermatology, Seoul, Korea

P086 Pigmented epithelioid melanocytoma – report of two casesCozzani R.1, Ferrua C.1, Molinari N.1, Gorostidy S.2, Quildrian S.3, del Águila R.11Instituto de Oncología Ágel H. Roffo, Dermatología, Ciudad Autonoma de Buenos Aires, Argentina, 2Instituto de Oncología Ágel H. Roffo, Patología, Ciudad Autonoma de Buenos Aires, Argentina, 3Instituto de Oncología Ágel H. Roffo, Cirugía de Partes Blandas, Ciudad Autonoma de Buenos Aires, Argentina

P087 Challenges in staging and surveillance of patients with Neurofibromatosis and cutaneous malignant melanomaChew P.R.1, Toh V.V.1, Kotwal A.11Castle Hill Hospital, Department of Plastic Surgery, Hull, United Kingdom

MEL

AN

OM

A

66

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P088 Superficial spreading melanoma detected during the examination of a cutaneous hornRussu L.1, Sprincenatu C.2, Russu M.3, Carjaliu A.A.4

1Bioderm Medical Center, Dermatology, Bucharest, Romania, 2Bioderm Medical Center, Bucharest, Romania, 3Bio Medica, Dermatology, Bucharest, Romania, 4Colentina Clinical Hospital, Dermatology, Bucharest, Romania

P089 Sporotrichoid spread of amelanotic metastatic malignant melanomaShpadaruk V.1, Mc Kiernan M.2, Fox R.2, Faust G.1, Barbieri A.2, Woo P.N.2

1University Hospitals of Leicester, Leicester, United Kingdom, 2Northampton Hospital, Northampton, United Kingdom

P090 Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect the phenotype switch?Haueis S.1, Kränzlin P.1, Cheng P.F.1, Mangana J.1, Dummer R.1, Goldinger S.M.11University Hospital of Zurich, Dermatology, Zurich, Switzerland

P091 Multiple primary melanomas – a single centre retrospective studyMenzies S.1, Rowley S.2, Ormond P.11St James’s Hospital, Dermatology, Dublin, Ireland, 2St James’s Hospital, Dublin, Ireland

P092 Increased risk of melanoma without pigmentation change. Results of Dermato fluoroscopy of ParkinsoniansLeupold D.1, Stankovic G.1, Riederer P.2, Monoranu C.M.3, Müller T.4

1Magnosco GmbH, Berlin, Germany, 2Universitätsklinik Würzburg, Zentrum für Seelische Gesundheit, Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Würzburg, Germany, 3Universität Würzburg, Pathologisches Institut, Abteilung für Neuropathology, Würzburg, Germany, 4Alexianer St. Joseph-Krankenhaus, Klinik für Neurologie, Berlin, Germany

P093 Melanoma patient support – what does your patient want?Mowbray M.1, Fraser S.2, Hancock E.2, Scorgie C.2

1NHS Fife, Scotland, Dermatology Department, Queen Margaret Hospital, Dunfermline, United Kingdom, 2NHS Fife, Scotland, Dunfermline, United Kingdom

P095 Cancer immunotherapies in metastatic melanoma: effectiveness of unique case-based education on clinical decision-makingRepetto P.1, Herrmann T.1, Warren C.1, Kadkhoda H.1, Scorzo M.2, Wiggins L.2, Luke J.3, Weber J.4

1Medscape Education, New York, United States, 2Society for Immunotherapy of Cancer, Milwaukee, United States, 3University of Chicago, Chicago, United States, 4New York University Medical Center, New York, United States

P096 My cancer plan: An information App for patients in a cancer diagnostics programmeHolm J.1, Eldon M.1, Stolle L.B.11Vejle Hospital, Odense University Hospital, Department of Plastic Surgery, Vejle, Denmark

P097 Malignant melanoma, is dominant at the ends: about a new observation acralBoudghene Stambouli O.11Faculty of Medicine, Dermatology, Tlemcen, Algeria

P098 Malignant melanoma and psoriasis acrolentigineuxBoudghene Stambouli O.11Faculty of Medicine, Dermatology, Tlemcen, Algeria

P099 Malignant melanoma lumbar and psoriasisBoudghene Stambouli O.11Faculty of Medicine, Dermatology, Tlemcen, Algeria

MEL

AN

OM

A

67

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P100 The prevalence of actinic keratosis and basal cell carcinoma and their association with UV radiation in the elderly Latvian populationBalcere A.1,2, Karls R.11Riga Stradiņš University, Department of Infectology and Dermatology, Riga, Latvia, 2University of Latvia, Department of Dermatovenerology, Riga, Latvia

P101 Merkel cell carcinoma in Franconia: Data on disease characteristics, treatment, and survivalKirchberger M.C.1, Schuler G.1, Leonhardt U.1, Hofmann L.1, Meyer M.2, Heinzerling L.11University Hospital Erlangen, Department of Dermatology, Erlangen, Germany, 2Centre for Early Cancer Detection and Cancer Registration, Bavarian Health and Food Safety Authority, Nuremberg, Germany

P102 CD47 expression in non-melanoma skin cancersAbbas O.1, Kurban M.11American University of Beirut Medical Center, Dermatology, Beirut, Lebanon

P103 A mutual mr21-thyroid hormone interplay regulates skin tumorigenesis and BCC formationDi Girolamo D.1, Ambrosio R.1, De Stefano M.A.1, Mancino G.1, Miro C.1, De Cicco E.1, Missero C.2, Salvatore D.1, Dentice M.11University of Naples Federico II, Clinical Medicine and Surgery, Naples, Italy, 2University of Naples “Federico II”, Biology, Naples, Italy

P104 Frequent loss of function mutations in TGFβR1 and TGFβR2 implicate hair follicle bulge stem cells as a cell of origin of cutaneous squamous cell carcinomaCammareri P.1, Rose A.2, Vincent D.1, Wang J.3, Nagano A.3, Libertini S.1, Ridgway R.1, Mchugh A.2, Pourreyon C.2, Spender L.2, Sapkota G.4, Purdie K.3, Proby C.2, Harwood C.3, Leigh I.2, Barker N.5, Karlsson S.6, Pritchard C.7, Marais R.8, Chelala C.3, South A.9, Sansom O.1, Inman G.2

1Cancer Research UK Beatson Institute, Glasgow, United Kingdom, 2University of Dundee, Division of Cancer Research, Dundee, United Kingdom, 3Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, United Kingdom, 4University of Dundee, Dundee, United Kingdom, 5Institute of Medical Biology, Singapore, Singapore, 6Lund University, Lund, Sweden, 7University of Leicester, Leicester, United Kingdom, 8CRUK Manchester Institute, Manchester, United Kingdom, 9Thomas Jefferson University, Philadelphia, United States

P105 Cooperation of Langerhans cells and NK cells guarding the epidermis during chemical carcinogenesisOrtner D.1, Tripp C.1, Komenda K.1, Dubrac S.1, Zelger B.1, Doppler W.2, Tymoszuk P.3, Boon L.4, Clausen B.5, Stoitzner P.11Medical University Innsbruck, Department of Dermatology, Venereology & Allergology, Innsbruck, Austria, 2Medical University Innsbruck, Section for Medical Biochemistry, Innsbruck, Austria, 3Medical University Innsbruck, Department of Internal Medicine VI, Innsbruck, Austria, 4Bioceros, Utrecht, Netherlands, 5Medical Center of the Johannes Gutenberg-University Mainz, Institute for Molecular Medicine, Mainz, Germany

P107 K36H protects skin from photocarcinogenesis via Bax/Bcl-2 and caspase dependent signaling pathway in human epidermal keratinocytesLyu J.‑L.1, Chu Y.1, Lin P.1, Wu J.‑S.1, Huang Y.‑H.1, Shu W.‑G.1, Wen K.‑C.1, Chiang H.‑M.1, Kuo Y.‑H.2,3

1China Medical University, Department of Cosmeceutics, Taichung, Taiwan, Republic of China, 2China Medical University, Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, Taichung, Taiwan, Republic of China, 3Asia University, Department of Biotechnology, Taichung, Taiwan, Republic of China

NO

N-M

ELA

NO

MA

SK

IN C

AN

CER

68

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P108 Minichromosome maintenance protein expression in squamous cell carcinomaStojkovic‑Filipovic J.1, Brasanac D.2, Bosic M.2, Lekic B.3

1Clinic of Dermatovenereology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, 2Institute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, 3Clinic of Dermatovenereology, Clinical Center of Serbia, Belgrade, Serbia

P109 A reduction in endogenous transforming growth factor-β signalling independently predicts increased tumour depth in human cutaneous squamous cell carcinomaRose A.1, Stephen C.2, Mitchell A.3, Rickaby W.4, Coates P.5, Proby C.6, Inman G.6

1University of Dundee, Division of Cancer Research and Plastic and Reconstructive Surgery, Dundee, United Kingdom, 2NHS Tayside, Plastic and Reconstructive Surgery, Dundee, United Kingdom, 3NHS Tayside, Department of Dermatology, Dundee, United Kingdom, 4St.Johns Institute of Dermatology, Dermatopathology, London, United Kingdom, 5Masaryk Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic, 6University of Dundee, Division of Cancer Research, Dundee, United Kingdom

P110 Mid-face location of primary basal cell carcinoma related to the aggressiveness of the cancerMawardi P.1,2, Kalim H.2, Kalim K.2, Enggar Fitri L.2, Mudigdo A.3, Wasita B.3, Oyong O.4

1Sebelas Maret University/Dr. Moewardi Hospital, Dermatovenereology Department, Surakarta, Indonesia, 2Brawijaya University, Faculty of Medicine, Malang, Indonesia, 3Sebelas Maret University/Dr. Moewardi Hospital, Pathology Department, Surakarta, Indonesia, 4Sebelas Maret University/Dr. Moewardi Hospital, Faculty of Medicine, Surakarta, Indonesia

P111 A Danish Cancer Center retrospective study on frozen section excisions of non-melanoma skin cancer in 2015Holm J.1, Barnkob S.1, Kjerkegaard U.K.1, Stolle L.B.11Vejle Hospital, Odense University Hospital, Department of Plastic Surgery, Vejle, Denmark

P112 Skin adnexal neoplasms: a real diagnosis challengeKelati A.1, Tahiri L.2, Harmouch T.2, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan II, Anatomopathology, Fez, Morocco

P113 Malignant adnexal neoplasms: Moroccan experienceKelati A.1, Tahiri L.2, Harmouch T.2, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan II, Anatomopathology, Fez, Morocco

P114 Dermoscopy of scalp BCC: variability according to clinical features and anatomic sub-siteSuppa M.1, Sollena P.2, Micantonio T.3, Longo C.4, Fargnoli M.C.3, Peris K.2

1Université Libre de Bruxelles, Hôpital Erasme, Department of Dermatology, Brussels, Belgium, 2Catholic University of the Sacred Heart, Department of Dermatology, Rome, Italy, 3University of L’Aquila, Department of Dermatology, L’Aquila, Italy, 4Arcispedale S. Maria Nuova-IRCCS, Dermatology and Skin Cancer, Reggio Emilia, Italy

P115 Characterisation of the molecular landscape of cutaneous squamous cell carcinomaProby C.1, Inman G.1, Wang J.2, Nagano A.2, Purdie K.3, Mladkova N.3, Lambert S.3, Gulati A.3, Sherwood V.1, Saville M.1, Chelala C.2, Harwood C.3, Leigh I.1,4, Cancer Research UK Skin Tumour Laboratory1University of Dundee, Ninewells Hospital, Division of Cancer Research, College of Medicine, Dundee, United Kingdom, 2Barts Cancer Institute, Queen Mary University of London, Bioinformatics Unit, London, United Kingdom, 3Blizzard Institute, Queen Mary University of London, Centre for Cutaneous Research, London, United Kingdom, 4Barts Cancer Institute, Queen Mary University of London, Centre for Tumour Biology, London, United Kingdom

NO

N-M

ELA

NO

MA

SK

IN C

AN

CER

69

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P116 The use of liquid-based cytology in diagnostics of basal cell carcinoma and actinic keratosisChristensen E.1, Eriksen Malone Isham S.2

1St. Olav’s University Hospital and Norwegian University of Science and Technology (NTNU), Department of Dermatology, and Department of Cancer Research and Molecular Medicine, Trondheim, Norway, 2St. Olavs University Hospital, Department of Medicine, Trondheim, Norway

P118 miRNAs as potential players RDEB cancer developmentWimmer M.1, Zauner R.1, Lettner T.1, Niklas N.2, Pröll J.2, Bauer J.W.1, Reichelt J.1, Wally V.11EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria, 2Red Cross Transfusion Service for Upper Austria, Linz, Austria

P119 The effects of Cxcl1 antagonist on UVB-induced skin inflammation in Xeroderma pigmentosum type A deficient miceKunisada M.1, Hosaka C.1, Nakano E.1, Enomoto H.2, Nishigori C.11Kobe University of Medicine, Dermatology, Kobe, Japan, 2Kobe University of Medicine, Division of Neural Differentiation and Regeneration, Department of Physiology and Cell Biology, Kobe, Japan

P120 5-fluorouracil loaded liposomes targeted with cetuximab inhibit skin squamous cell carcinoma in xenograft animal modelPetrilli R.1,2, Eloy J.O.1,2, Lee R.J.2, Lopez R.F.V.11College of Pharmaceutical Sciences of Ribeirão Preto – University of Sao Paulo (USP), Ribeirao Preto, Brazil, 2College of Pharmacy – The Ohio State University (OSU), Columbus, United States

P121 VISMONEO – a phase II study assessing vismodegib in the neoadjuvant treatment of locally advanced basal cell carcinoma – patients characteristicsBasset‑Seguin N.1, Dupuy A.2, Saiag P.3, Dalac‑Rat S.4, Guillot B.5, Routier E.6, Leccia M.T.7, Duhamel A.8, Mirabel X.9, Benbouta I.8, Mirakovska L.8, Meddour D.8, Dib M.8, Mahmoudi A.10, Guerreschi P.8, Mortier L.8

1Hopital Saint-Louis, Paris, France, 2Centre d’Oncodermatologie CLCC/CHU de Rennes, Rennes, France, 3Hôpital Ambroise Paré, Boulogne Billancourt, France, 4CHU de Dijon, Dijon, France, 5CHU de Montpellier, Montpellier, France, 6Institut Gustave Roussy, Villejuif, France, 7CHU de Grenoble, Grenoble, France, 8CHRU de Lille, Lille, France, 9Centre Oscar Lambret, Lille, France, 10Laboratoires Roche, Boulogne Billancourt, France

P122 Health-Related Quality of Life (HRQoL) analysis by skindex-16 in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in patients (pts) with multiple basal cell Carcinomas (BCCs)Dréno B.1, Hauschild A.2, Maher I.3, Zloty D.4, Labeille B.5, Grob J.‑J.6, Puig S.7, Karagiannis T.8, Gilberg F.9, Schadendorf D.10, Kunstfeld R.11, Rogers G.12

1Nantes University, Nantes, France, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3Saint Louis University Medical School, St. Louis, United States, 4University of British Columbia, Vancouver, Canada, 5University Hospital of Saint-Etienne, Saint-Etienne, France, 6Timone Hospital, Marseille, France, 7Hospital Clinic de Barcelona, Barcelona, Spain, 8Genentech, Inc., South San Francisco, United States, 9Hoffman-La Roche, Ltd, Basel, Switzerland, 10Universitätsklinikum Essen, Essen, Germany, 11Medical University of Vienna, Vienna, Austria, 12Tufts University School of Medicine, Boston, United States

NO

N-M

ELA

NO

MA

SK

IN C

AN

CER

70

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P123 Sonidegib safety in patients with locally advanced Basal Cell Carcinoma and efficacy based on tumor aggressivenessLear J.1, Guminski A.2, Gutzmer R.3, Migden M.4, Kudchadkar R.5, Lewis K.6, Dirix L.7, Plummer R.8, Stratigos A.9, Chang A.L.10, Trefzer U.11, Loquai C.12, Kaatz M.13, Combemale P.14, Mone M.15, Castro H.16, Yi T.15, Sellami D.15, Dummer R.17

1Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Royal North Shore Hospital, St Leonards, Australia, 3Medizinische Hochschule Hannover, Hannover, Germany, 4The University of Texas MD Anderson Cancer Center, Houston, United States, 5Winship Cancer Institute of Emory University, Atlanta, United States, 6University of Colorado Cancer Center, Aurora, United States, 7Sint-Augustinus Ziekenhuis, Antwerp, Belgium, 8Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 9Andreas Syggros Hospital, University of Athens, Athens, Greece, 10Stanford University School of Medicine, Redwood City, United States, 11Dermatologikum Berlin, Berlin, Germany, 12University Medical Center Mainz, Mainz, Germany, 13University Hospital Jena, Jena, Germany, 14Centre Leon Bérard, Lyon, France, 15Novartis Pharmaceuticals Corporation, East Hanover, United States, 16Novartis Pharma AG, Basel, Switzerland, 17UniversitätsSpital Zürich, Skin Cancer Center, University Hospital, Zürich, Switzerland

P124 Sclerodermiform basal cell carcinoma and surgical treatment. Where is the surgery limit?Ciudad Blanco C.1, Parra Blanco V.2, Suárez Fernández R.11Hospital General Universitario Gregorio Marañón, Dermatology, Madrid, Spain, 2Hospital General Universitario Gregorio Marañón, Pathology, Madrid, Spain

P126 Utilising intraoperative frozen section in the surgical management of patients with non-melanocytic skin cancer improve outcomesTeng T.Y.1, Chia J.C.H.2, Hing E.C.H.1, Ong W.C.1, Lim J.1, Lim T.C.1, Yap Y.L.11Division of Plastic, Reconstructive and Aesthetic Surgery, National University Health System, Singapore, Singapore, 2University of Sydney, Sydney, Australia

P127 Successful use of grenz rays for DSAP: Report of 8 casesRamelyte E.1,2, Bylaite‑Bucinskiene M.2, Dummer R.1, Imhof L.11University Hospital Zurich, Dermatology, Zurich, Switzerland, 2Vilnius University, Dermatovenereology, Vilnius, Lithuania

P128 A versatile flap for reconstruction of partial pinna defects after tumour resection – The pre-auricular flapJayarajan R.1, Agarwal R.11University Hospitals of Leicester, Plastic Surgery, Leicester, United Kingdom

P129 Long-term follow-up of two patients with Nevoid basal cell carcinoma syndrome (NBCCS) treated with VismodegibVan Eecke L.1, Wolter P.2, Bechter O.2, Rogiers A.2, De Smedt J.1, Garmyn M.11UZLeuven, Dermatology, Leuven, Belgium, 2UZLeuven, Oncology, Leuven, Belgium

P130 Erythroplasia of Queyrat (EQ): a diagnostic and therapeutic challengeDrljevic I.1, Dajic Hrvanovic S.2

1University of Zenica, Faculty of Health, Private Clinic for Dermatovenereology ‘Dr Drljevic’, Sarajevo, Bosnia and Herzegovina, 2Cantonal Hospital Zenica, Dermatovenereology Department, Zenica, Bosnia and Herzegovina

P131 Prospective randomised control trial comparing electrochemotherapy and surgery for the primary treatment of basal cell carcinomaClover A.J.1, Salwa S.2, McKiernan J.1, Buckley C.1, Bourke M.2, Kelly E.J.1, O’Sullivan S.1, Soden D.M.2

1University College Cork, Department of Plastic Surgery, Cork, Ireland, 2University College Cork, Cork Cancer Research Centre, Cork, Ireland

NO

N-M

ELA

NO

MA

SK

IN C

AN

CER

71

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

v.forghieri

Evidenziato


P132 Targeting tumor metabolism in the therapy of aggressive squamous cell carcinoma in patients with epidermolysis bullosaWelponer T.1, Piñón Hofbauer J.1, Gruber C.1, Kienzl M.1, Aminzadeh‑Gohari S.2, Feichtinger R.2, Lang R.1, Bauer J.W.3, Kofler B.2, Reichelt J.11EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, Paracelsus Medical University, Salzburg, Austria, 2Laura Bassi Centre of Expertise-THERAPEP, Research Program for Receptor Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria, 3Department of Dermatology, Paracelsus Medical University, Salzburg, Austria

P133 Photodynamic therapy with methylaminolevulinate (MAL-PDT) for superficial and nodular basal cell carcinoma (BCC): clinical studyDzybova E.1, Vasilevskaya E.1, Vardanyan K.1, Potekaev N.11European Medical Center, Moscow, Russian Federation

P134 Analysis of patients (pts) with and without basal cell carcinoma nevus syndrome (BCCNS) in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in pts with multiple Basal Cell Carcinomas (BCCs)Kunstfeld R.1, Zloty D.2, Tang J.3, Basset‑Séguin N.4, Bissonnette R.5, Grob J.‑J.6, Maher I.7, Bergström D.8, Gilberg F.8, Dréno B.9, Rogers G.10, Schadendorf D.11

1Medical University of Vienna, Vienna, Austria, 2University of British Columbia, Vancouver, Canada, 3Stanford University, La Jolla, United States, 4Hôpital Saint Louis, Paris, France, 5Innovaderm Research, Inc., Montreal, Canada, 6Aix-Marseille University, Hopital Timone APHM, Marseille, France, 7Saint Louis University Medical School, St. Louis, United States, 8Hoffman-La Roche, Ltd, Basel, Switzerland, 9Nantes University, Nantes, France, 10Tufts University School of Medicine, Boston, United States, 11Universitätsklinikum Essen, Essen, Germany

P135 Development of muscle spasm during Vismodegib treatment and the effect of treatment interruptions: exploratory analyses from the STEVIE studyKunstfeld R.1, Hauschild A.2, Basset‑Séguin N.3, Hansson J.4, Dréno B.5, Mortier L.6, Ascierto P.7, Licitra L.8, Dimier N.9, Xynos I.9, Grob J.‑J.10

1Medical University of Vienna, Vienna, Austria, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3Hôpital Saint Louis, Paris, France, 4Karolinska University Hospital, Solna, Stockholm, Sweden, 5Nantes University, Nantes, France, 6University of Lille 2, Lille Regional University Hospital, Lille, France, 7Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy, 8Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, 9Roche Products, Ltd., Welwyn Garden City, United Kingdom, 10Aix-Marseille University, Hopital Timone APHM, Marseille, France

P136 A randomized split-face clinical trial of daylight photodynamic therapy with methyl aminolaevulinate vs ingenol mebutate gel for the treatment of actinic keratosis of the face and scalpCalzavara‑Pinton P.1, Moggio E.2, Arisi M.2, Zane C.11University of Brescia, Brescia, Italy, 2University of Brescia, Dermatology, Brescia, Italy

P137 Clinical care of actinic keratoses: Documentation of number and treatment modalities in a case register project in GermanyLeiter U.1, Weichenthal M.2

1University of Tuebingen, Dermatology, Tuebingen, Germany, 2University of Kiel, Dermatology, Kiel, Germany

P138 Ingenol mebutate versus daylight methyl-aminolevulinate photodynamic therapy for the treatment of actinic keratoses: an intraindividual comparative analysisFai D.1, Mavilia L.2, Genovese G.2, Fai C.11Daniele Romasi Hospital, Dermatology, Gagliano del Capo, Italy, 2San Raffaele, Dermatology, Milano, Italy

NO

N-M

ELA

NO

MA

SK

IN C

AN

CER

72

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P139 Daylight photodynamic therapy with methyl aminolevulinate cream versus diclofenac plus hyaluronic acid gel for the treatment of multiple actinic keratoses: An indirect comparisonCalzavara‑Pinton P.1, Zane C.1, Pacou M.2, Szeimies R.‑M.3

1University of Brescia, Department of Dermatology, Brescia, Italy, 2Amaris, Paris, France, 3Klinikum Vest GmbH Academic Teaching Hospital, Dept. of Dermatology and Allergology, Recklinghausen, Germany

P140 Adapting a UV-induced skin carcinogenesis model in immunocompetent SKH1 mice to therapeutic testing of compounds against skin cancerChristensen P.1, Høyer‑Hansen M.H.1, Skak K.11LEO Pharma, Ballerup, Denmark

P141 Photodynamic therapy with methylaminolevulinate (MAL-PDT) for actinic keratosis (AK): clinical studyDzybova E.1, Vasilevskaya E.1, Potekaev N.1, Vardanyan K.11European Medical Center, Moscow, Russian Federation

P142 What’s new in the dermoscopy of actinic keratosis? A study of 232 casesKelati A.1, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco

P143 Actinic keratosis induces angiogenesisValero T.1, Neumüller K.2, Krall C.3, Petzelbauer P.11Medical University Vienna, Department of Dermatology, Vienna, Austria, 2Medical University Vienna, Skin & Endothelium Research Division (SERD), Vienna, Austria, 3Medical University Vienna, Institute of Medical Statistics, Vienna, Austria

P144 The role of histological verification of metastases in onco-dermatologyPánczél G.1, Plótár V.2, Bőcs K.3, Liszkay G.11National Institute of Oncology, Oncodermatology, Budapest, Hungary, 2National Institute of Oncology, Molecular Pathology, Budapest, Hungary, 3National Institute of Oncology, Diagnostic Radiology, Budapest, Hungary

P145 Conventional PDT vs fractional CO2 laser-assisted-PDT with short incubation time in skin cancer prevention: a randomized intraindividual comparison study with 12-month follow-upVrani F.1, Sotiriou E.1, Vakirlis E.1, Lazaridou E.1, Ioannides D.11Aristotle University, First Dermatology Department, Thessaloniki, Greece

P146 Basal Cell Carcinoma: Smartphone app control vs. clinical controlEldon M.1, Hedelund L.1, Lorentzen H.F.1, Thormann H.2, Bjørn Stolle L.3

1Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark, 2Odense University Hospital, Private Practice Dermatologist, Vejle, Denmark, 3Odense University Hospital, Department of Plastic Surgery, Odense, Denmark

P147 Postoperative risk factors of organ transplant recipients following dermatosurgical proceduresKröpfl L.1, Schadendorf D.2, Hillen U.2, Klode J.2

1Praxis Buljanovic-Kröpfl, Dermatologie, Essen, Germany, 2Universitätsklinikum Essen, Dermatologie, Essen, Germany

P148 Chronic radiation dermatitis induced by radiotherapy associated with cisplatin in a case of hypopharyngeal cancerJerkovic Gulin S.1, Chiriac A.2

1General Hospital Sibenik, 1 Department of Infectious Diseases, Dermatology and Venereology, Sibenik, Croatia, 2Dermatology Department, Nicolina Medical Centre, Apollonia University, „P.Poni“ Research Institute of Macromolecular Chemistry, Iasi, Romania

NO

N-M

ELA

NO

MA

SK

IN C

AN

CER

73

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P149 Basal cell carcinoma axillary: about 02 casesBoudghene Stambouli O.11Faculty of Medicine, Dermatology, Tlemcen, Algeria

P150 Dermal substitutes in cutaneous oncology: A single center experienceCampagnari M.1, Jafelicci A.S.2, Carneiro H.A.2, Brechtbühl E.R.1, Bertolli E.1, Duprat Neto J.P.11AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Surgical Oncology Residence, São Paulo, Brazil

P151 A rare case of basal cell carcinoma of the face associated with parotid in-transit metastasisTeng T.Y.1, Xu X.1, Nallathamby V.1, Yap Y.L.1, Lim J.1, Lim T.C.1, Ong W.C.11Divison of Plastic, Reconstructive and Aesthetic Surgery, National University Health System, Singapore, Singapore

P152 Two cases of squamous cell carcinoma associated with seborrhoeic keratosesTan W.P.1, Lim C.1, Tee S.I.11National Skin Centre, Singapore, Singapore

P153 Weekly cisplatin, epirubicin, and paclitaxel induced a durable response in two cases of metastatic extramammary Paget’s diseaseHirai I.1, Funakoshi T.11Keio University School of Medicine, Dermatology, Tokyo, Japan

P154 An unexpected diagnosis of a chronic ulcer on lower extremityAçıkgöz G.1, Küçük K.1, Kılınç M.2

1Gülhane School of Military Medicine, Dermatology, Ankara, Turkey, 2Gülhane School of Military Medicine, Pathology AD, Ankara, Turkey

P155 Gorlin syndrome with locally advanced basal cell carcinomas treated with vismodegibAbeldaño A.1, Maskin M.1, Arias M.1, Gonzalez A.2, Benedetti A.1, Lamas C.11Hospital Gral. de Agudos Dr. Cosme Argerich. Universidad de Buenos Aires, Buenos Aires, Argentina, 2Hospital Dr. Angel Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina

P156 Primary cutaneous mucinous adenocarcinoma: sex hormone receptors a clue to the aetiology Tang H.K.C.1, Housa D.2, Patel G.K.11Prince Philip Hospital, Dermatology, Llanelli, United Kingdom, 2Prince Philip Hospital, Pathology, Llanelli, United Kingdom

P157 The rate and pattern of metastasis from head & neck cutaneous squamous cell carcinomaAinscough S.1, Brown N.2

1York Teaching Hospitals, Head & Neck, York, United Kingdom, 2York Teaching Hospitals, York, United Kingdom

P158 Dermatofibrosarcoma protuberans: diagnosis, treatment and follow-up of a case series of 8 patientsPavlova E.1, Stanimirov P.2, Slavkova S.3, Troyanova P.11University Hospital Tsaritsa Yoanna-ISUL, Outpatient Department, Sofia, Bulgaria, 2University Hospital Alexandrovska, Department of Maxillo Facial Surgery, Sofia, Bulgaria, 3HELIOS Vogtland-Klinikum Plauen, Department of Dermatology and Allergology, Plauen, Germany

P159 Overgrowth of undifferentiated pleomorphic sarcoma during vismodegib treatment of locally advanced basal cell carcinoma – a case reportMijuskovic Z.P.1, Brasanac D.2, Sijan G.3, Rajovic M.3, Kandolf‑Sekulovic L.11Faculty of Medicine, Military Medical Academy, Clinic of Dermatology and Venereology, Belgrade, Serbia, 2Faculty of Medicine, University of Belgrade, Institute of Pathology, Belgrade, Serbia, 3Faculty of Medicine, Military Medical Academy, Clinic of Plastic Surgery and Burns, Belgrade, Serbia

NO

N-M

ELA

NO

MA

SK

IN C

AN

CER

74

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P160 Expression of HER family of tyrosine kynase receptors, proliferation marker Ki67 and protein p53 in multiple and solitary cutaneous squamous cell carcinomaLedic Drvar D.1, Lipozencic J.2, Bukvic Mokos Z.1, Ilic I.3, Knezevic F.4

1University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 2The Academy of Medical Sciences of Croatia, Zagreb, Croatia, 3University Hospital Centre Zagreb, Department of Pathology and Cytology, Zagreb, Croatia, 4Clinical Hospital ‘Sveti Duh’ Zagreb, Department of Pathology and Cytology, Zagreb, Croatia

P161 Characteristic of immune status of patients with basal cell carcinoma (BCC), who live in the industrial district with the highest incidence of “non-melanoma skin cancers” (NMSC) in South UralPisklakova T.1, Ekimova O.2

1South Ural State University, Department of Service and Technologies of Art Processing Materials, Chelyabinsk, Russian Federation, 2Regional Dermatology and Venereology Clinic № 3, Outpatient Department, Chelyabinsk, Russian Federation

P162 Lymphomatoid papulosis type D: do not ignore this entity and not to be confused with aggressive lymphoma CD8Boudghene Stambouli O.11Faculty of Medicine, Dermatology, Tlemcen, Algeria

P163 Multiple giant warts (Buschke-Lowenstein tumor) with malignant transformationBoudghene Stambouli O.11Faculty of Medicine, Dermatology, Tlemcen, Algeria

P164 Non-melanoma skin cancer operative records – introduction of a proforma for complete documentationJayarajan R.1, Ibrahim N.1, Sayed L.11University Hospitals of Leicester, Plastic Surgery, Leicester, United Kingdom

P165 Keratoacanthoma-like metastasis as the presenting sign of lung carcinoma: a case reportĐurinec P.1, Radoš J.1, Kostović K.1, Ilić I.2, Marinović B.11University of Zagreb School of Medicine, University Hospital Center Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 2University of Zagreb School of Medicine, University Hospital Center Zagreb, Department of Pathology, Zagreb, Croatia

P166 Pigmented Bowen’s disease – how to recognize it? A case reportRados J.1, Loncaric D.1, Zuzul K.1, Curkovic D.1, Marinovic B.11UHC Zagreb and School of Medicine, University of Zagreb, Department of Dermatovenereology, Zagreb, Croatia

P167 Microcystic adnexal carcinoma in atypical site (pubic region): clinic and dermatoscopyAstorino S.1, Carelli G.2, Pasquini P.3

1Unit of Dermatology and s.t.d., ‘Celio’ Military Hospital, Rome, Italy, 2Army School of Health, Rome, Italy, 3Histopathology Service, ‘Celio’ Military Hospital, Rome, Italy

P168 Merkel cell carcinoma of the trunk and extremities in ArgentinaCozzani R.1, Daffinoti A.2, Cervelo G.2, Gerino J.2, del Aguila R.1, Chapela J.2, Quildrian S.2

1Instituto de Oncología Ágel H. Roffo – University of Buenos Aires, Dermatology, Ciudad Autonoma de Buenos Aires, Argentina, 2Instituto de Oncología Ágel H. Roffo – University of Buenos Aires, Soft Tissue Tumors, Ciudad Autonoma de Buenos Aires, Argentina

P169 Clinical behaviour of Merkel cell carcinoma- the York experienceKrishnan O.1, Brown J.1, Brown N.11York Hospital, Oral & Maxillofacial Surgery, York, United Kingdom

NO

N-M

ELA

NO

MA

SK

IN C

AN

CER

75

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P170 Diagnostic value of plasmacytoid dendritic cells in differentiating primary follicular mucinosis (FM) from lymphoma-associated FMAbbas O.1, Kurban M.11American University of Beirut Medical Center, Dermatology, Beirut, Lebanon

P171 Biological properties of T-cell lymphoma (Mycosis fungoides) in correlation with the clinical picture, stage and patient outcome in Croatia – ten-year follow-upJerkovic Gulin S.1, Ceovic R.2,3, Ilic I.4, Kostovic K.2,3, Marinovic B.2,3

1General Hospital Sibenik, Infectious Diseases, Dermatology and Venereology, Sibenik, Croatia, 2University of Zagreb School of Medicine, Zagreb, Croatia, 3University Hospital Center Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 4University Hospital Center Zagreb, Department of Pathology and Cytology, Zagreb, Croatia

P172 Defining the mimics and the clinico-histological diagnosis criteria for Mycosis fungoides in order to minimize misdetectionKelati A.1, Harmouch T.2, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan II, Anatomopathology, Fez, Morocco

P173 Cutaneous T cell infiltrates – Immunohistochemical and genomic issuesProca Nicula A.1, Baderca F.2,3, Solovan C.1,2

1University Clinic of Dermatology and Venereology, Timisoara, Romania, 2“Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania, 3Emergency City Hospital, Service of Pathology, Timisoara, Romania

P175 Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoidesWieser I.1,2, Wang C.1, Alberti‑Violetti S.1, Lyons G.3, Tran C.4, Talpur R.1, Duvic M.11The University of Texas M.D. Anderson Cancer Center, Dermatology, Houston, United States, 2Paracelsus Medical University, Department of Dermatology, Salzburg, Austria, 3The University of Texas, MD Anderson Cancer Center, Department of Biostatistics, Houston, United States, 4University of North Texas Health Science Center, Texas College of Osteopathic Medicine, Fort Worth, United States

P176 Frequency increase, clinical features, and survival outcomes of cutaneous lymphoma in Morocco: A subgroup analysis per 10-year periodKelati A.1, Safae Z.1, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco

P177 Frequency and risk factors for secondary malignancies in patients with mycosis fungoidesCengiz F.P.1, Emiroglu N.1, Biyik Ozkaya D.1, Gulsel Bahali A.1, Su O.1, Onsun N.11Bezmialem Vakif University, Dermatology and Veneorology, Istanbul, Turkey

P178 Prognostic factors of patients with mycosis fungoidesBahalı A.G.1, Su Ö.1, Cengiz F.P.1, Emiroğlu N.1, Bıyık Özkaya D.1, Onsun N.11Bezmialem Vakif University, Dermatology, İstanbul, Turkey

P179 Long-term follow-up of benign course of lymphomatoid papulosis – a case reportBartolić L.1, Jović A.2, Radoš J.2, Ilić I.3, Kostović K.2

1Private Specialist of Dermatology and Venereology Practice Dr. Kedmenec Bartolić, Čakovec, Croatia, 2University Hospital Center Zagreb, Department of Dermatology and Venereology, School of Medicine, Zagreb, Croatia, 3University Hospital Center Zagreb, Department of Pathology, School of Medicine, Zagreb, Croatia

CUTA

NEO

US

LYM

PHO

MA

76

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P180 Periorbital involvement in early stage mycosis fungoidesWieser I.1,2, Bush A.E.1, Dabaja B.S.3, Duvic M.11The University of Texas M.D. Anderson Cancer Center, Department of Dermatology, Houston, United States, 2Department of Dermatology, Paracelsus Medical University, Salzburg, Austria, 3The University of Texas M.D. Anderson Cancer Center, Department of Radiation Oncology, Houston, United States

P181 Hypopigmented mycosis fungoides versus mycosis fungoides with concomitant hypopigmented lesions: same disease or different variants of mycosis fungoides? Moroccan experienceKelati A.1, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco

P182 Folliculotropic mycosis fungoides: clinical and histopathological features in a Moroccan patient seriesKelati A.1, Zinoune S.2, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan II, Fez, Morocco

P183 An unusual case of palmoplantar eczema?Mokbel R.1, Chinthapalli S.1, Rizvi H.1, Cerio R.1, Goldsmith P.11Royal London Hospital, London, United Kingdom

P184 Primary extramedullary plasmacytoma presenting as chronic ulcerative, whitish plaques on the oral mucosaKim J.E.1, Han J.H.1, Woo Y.J.1, Kang H.11St. Paul’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of

P185 Cutaneous T cell lymphoma in a patient with primary biliary cirrhosisGuler Ozden M.1, Ayyıldızt T.2, Nilgün Ş.1, Tayyar C.11Ondokuz Mayıs University Medical Faculty, Dermatology, Samsun, Turkey, 2Ondokuz Mayıs University, Medical Faculty, Gastroenterology, Samsun, Turkey

P186 Cutaneous manifestations of haematologic malignancies – two case reportsSchmid M.A.1,2, Rainer G.1,2, Udvardi A.1,2, Birkner T.3, Chott A.4, Klapper W.5, Volc‑Platzer B.1,2

1Donauspital SMZO, Department of Dermatology, Vienna, Austria, 2Karl Landsteiner Institute for Pediatric Dermatology, Vienna, Austria, 3Donauspital SMZO, Institute of Pathology, Vienna, Austria, 4Wilhelminenspital, Institute of Pathology, Vienna, Austria, 5University-Hospital Schleswig-Holstein, Department of Pathology, Kiel, Germany

P187 Primary cutaneous CD30+ lymphoproliferative disorders: the beast or the beauty?Kelati A.1, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco

P188 Plasmablastic lymphoma presenting in the skin: report of two clinical casesFernandes I.1, Cabral R.2, Mota F.3, Mesquita B.4, Selores M.3, Coutinho J.5, Lima M.2

1Hospital de Santo António, Centro Hospitalar do Porto, Dermatology; Multidisciplinary Consultation for Cutaneous Lymphomas and Mastocytosis, Porto, Portugal, 2Hospital de Santo António, Centro Hospitalar do Porto, Hematology; Multidisciplinary Consultation for Cutaneous Lymphomas and Mastocytosis, Porto, Portugal, 3Hospital de Santo António, Centro Hospitalar do Porto, Dermatology, Porto, Portugal, 4Hospital de Vila Real, Centro Hospitalar de Trás-os-Montes e Alto Douro, Hematology, Porto, Portugal, 5Hospital de Santo António, Centro Hospitalar do Porto, Hematology, Porto, Portugal

CUTA

NEO

US

LYM

PHO

MA

77

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P189 Primary cutaneous lymphoma of 20 cases: CHU experience of Department of Dermatology Tlemcen (West Algeria)Boudghene Stambouli O.1, Nawel A.2

1Faculty of Medicine University Aboubakr Belkaid, Dermatology, Tlemcen, Algeria, 2Faculty of Medicine University Aboubakr Belkaid, Tlemcen, Algeria

P190 Mycosis fungoides in its pseudo leprous form of pigmented skinBoudghene Stambouli O.1, Nawel A.2

1Faculty of Medicine, Dermatology, Tlemcen, Algeria, 2Faculty of Medicine University Aboubakr Belkaid, Dermatology, Tlemcen, Algeria

P191 Immune checkpoints in Merkel cell carcinomaWehkamp U.1, Stern S.1, Krüger S.2, Röcken C.2, Egberts F.11University Hospital Schleswig-Holstein, Department of Dermatology, Kiel, Germany, 2University Hospital Schleswig-Holstein, Institute of Pathology, Kiel, Germany

P192 Evaluation of the immunogenicity of viral epitopes in a cancer immunogene therapy approach for squamous cell carcinoma in RDEBReichl V.M.1, Kienzl M.1, Stöcklinger A.2, Tockner B.1, Reichelt J.1, Gruber C.1, Pinon‑Hofbauer J.11EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University Hospital of the Paracelsus Medical University, Salzburg, Austria, 2Department of Molecular Biology, University of Salzburg, Salzburg, Austria

P193 Nodular fasciitis: an underdiagnosed entityFerrario D.1, Luna A.1, Molinari L.1, Rodriguez Kowalczuc M.V.1, Volonteri V.1, Galimberti G.11Hospital Italiano, Buenos Aires, Argentina

P194 Solitary cutaneous metastasis of renal clear cell carcinoma on nasal tipGómez‑Zubiaur A.1, Trasobares‑Marugán L.1, Aboín‑González S.1, Medina‑Expósito I.2, Villalobos‑León M.L.3

1Príncipe de Asturias Hospital, University of Alcalá, Dermatology and Venereology Department, Alcalá de Henares, Spain, 2Príncipe de Asturias Hospital, University of Alcalá, Anatomical Pathology Department, Alcalá de Henares, Spain, 3Príncipe de Asturias Hospital, University of Alcalá, Clinical Oncology Department, Alcalá de Henares, Spain

P195 Successful treatment of locally advanced Merkel cell carcinoma with somatostatin analogue-lanreotideLengyel Z.1, Horvath Z.1, Gyulai R.11University of Pécs, Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary

P196 Merkel cell carcinoma with pancreatic metastasis: Case report and review of literatureCosta Filho E.D.P.R.1, Falcão A.C.A.1, Neotti T.2, Costa Junior W.L.3, Costa F.D.2, Bertolli E.4, Duprat Neto J.P.4

1AC Camargo Cancer Center, Surgical Oncology Residence, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São Paulo, Brazil, 3AC Camargo Cancer Center, Abdominal Surgery Department, São Paulo, Brazil, 4AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil

ORP

HA

N S

KIN

CA

NCE

R

78

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P197 Kaposi sarcoma: General aspect and radiotherapyOuaz H.1, Tebra S.1, Zrafi W.1, Bouaouina N.11University Hospital Farhat Hached, Radiation Oncology, Sousse, Tunisia

P198 Test-retest reproducibility and validity of a skin cancer risk factor questionnaireJoosten V.H.M.J.1, Wouters L.1, Kelleners‑Smeets N.W.J.1, Nelemans P.J.2

1GROW Research Institute for Oncology and Developmental Biology, Dermatology, Maastricht, Netherlands, 2CAPHRI School for Public Health and Primary Care, Epidemiology, Maastricht, Netherlands

P199 Skin cancer incidence in Latvia 2007–2014: comparison with Estonia and LithuaniaOzola E.1, Donina S.1,2

1Rigas Stradins University, Riga, Latvia, 2Riga East University Hospital, Riga, Latvia

P200 Sunbed use: prevalence and estimated risk of melanoma across European countries participating in the Euromelanoma prevention campaignSuppa M.1, Gandini S.2, Bulliard J.L.3, Hassane N.1, del Marmol V.11Université Libre de Bruxelles, Hôpital Erasme, Department of Dermatology, Brussels, Belgium, 2European Institute of Oncology, Division of Epidemiology, Biostatistics, Milan, Italy, 3Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland

P201 Trends in morbidity of Kaposi s sarcoma among solid organ transplant recipientsSorin D.1, Hodak E.1,2, Mor E.2,3, Birkenfeld S.4, Davidovici B.11Rabin Medical Center – Beilinson Hospital, Dermatology, Petach Tikva, Israel, 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Rabin Medical Center – Beilinson Hospital, Department of Organ Transplantation, Petach Tikva, Israel, 4Clalit Health Services, Tel Aviv, Israel

P202 Skin cancer: what do you know about it? Moroccan studyKelati A.1, Meziane M.2, Mernissi F.Z.11Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan II, Fez, Morocco

P203 Development and application of in vitro keratinocyte assays incorporating viability, p38, p53 endpoints to evaluate the protection efficacy of sunscreens against UV radiationStilla A.1, Walter N.1, Hewitt N.J.2, Kunze G.11Galderma-Spirig Spirig Pharma AG, Egerkingen, Switzerland, 2SWS, Erzhausen, Germany

P204 Toxiderma drug buprenorphine (Temgesic) in a patient with lung cancer with brain metastasesBoudghene Stambouli O.11Faculty of Medicine, Dermatology, Tlemcen, Algeria

P205 p16 expression in seborrheic keratosis in relation to the presence of Merkel cell polyomavirusRennspiess D.1, Hillen L.1, Speel E.‑J.1, Haugg A.2, Winnepenninckx V.1, zur Hausen A.11Maastricht University Medical Center, Pathology, Maastricht, Netherlands, 2Maastricht University Medical Center, Department of Pathology and GROW-School for Oncology & Developmental Biology, Maastricht, Netherlands

SKIN

CA

NCE

R IN

GEN

ERA

L

79

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P206 MicroRNA-203 inversely correlates with differentiation grade and suppresses cutaneous squamous cell carcinoma growth via targeting c-myc oncogeneLohcharoenkal W.1, Harada M.2, Lovén J.3, Meisgen F.1, Xu Landén N.1, Zhang L.1, Lapins J.1, Das Mahapatra K.1, Shi H.1, Nissinen L.4, Kähäri V.‑M.4, Ståhle M.1, Sonkoly E.1, Grander D.2, Arsenian‑Henriksson M.3, Pivarcsi A.1

1Karolinska Institutet, Medicine, Stockholm, Sweden, 2Karolinska Institutet, Oncology-Pathology, Stockholm, Sweden, 3Karolinska Institutet, Microbiology, Tumor and Cell Biology (MTC), Stockholm, Sweden, 4University of Turku and Turku University Hospital, Dermatology, Turku, Finland

P207 Recurrent nevus vs. recurrent melanoma: Differences in epidemiology and BRAFV600E-mutation statusWoltsche N.1, Massone C.1, Klymiuk I.2, Guelly C.2, Zweiker D.3, Bulijan M.1, Hofmann‑Wellenhof R.1, Zalaudek I.1

1Medical University of Graz, Dermatology & Venereology, Graz, Austria, 2Medical University of Graz, Centre of Medical Research, Graz, Austria, 3Medical University of Graz, Internal Medicine, Graz, Austria

P208 In vivo multiphoton tomography of skin cancerKoenig K.1

1Universität des Saarlandes, Biophotonik und Lasertechnologie, Saarbrücken, Germany

P210 Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006 Blank Ch.1, Lorigan P.2, Schachter J.3, Robert C.4 , Ribas A.5, Long G. V.6, Arance A.7, Mortier L.8, Daud A.9, Carlino M. S.10, McNeil C.11, Lotem M.12, Larkin J.13, Neyns B.14, Petrella T. M.15, Hamid O.16, Zhou H.17, Ebbinghaus S.17, Ibrahim N.17, Grob J.‑J.18

1Netherlands Cancer Institute, Amsterdam, Netherlands; 2University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom; 3Ella Lemelbaum Institute for Melanoma, Sheba Medical Center, Tel Hashomer, Israel; 4Gustave Roussy and Paris-Sud University, Villejuif, France; 5University of California, Los Angeles, Los Angeles, CA; 6Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital, Sydney, Australia; 7Hospital Clinic de Barcelona, Barcelona, Spain; 8Université Lille, Centre Hospitalier Régional Universitaire de Lille, Lille, France; 9University of California, San Francisco, San Francisco, CA; 10Westmead and Blacktown Hospitals, Melanoma Institute Australia, and the University of Sydney, Sydney, Australia; 11Chris O’Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown, Australia; 12Sharett Institute of Oncology, Hadassah Hebrew Medical Center, Jerusalem, Israel; 13Royal Marsden Hospital, London, United Kingdom; 14Universitair Ziekenhuis Brussel, Brussels, Belgium; 15Sunnybrook Health Sciences Center, Toronto, ON; 16The Angeles Clinic and Research Institute, Los Angeles, CA; 17Merck & Co., Inc., Kenilworth, NJ; 18Aix Marseille University, Hôpital de la Timone, Marseille, France

LATE

-BRE

AK

ING

80

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P211 Volume and tissue composition measurements of lymphoedema with DXA scan: A novel way of measuring lymphoedemaGjorup C.A.1, Hendel H.W.2, Christensen K.B.3, Dahlstrøm K.1, Drzewiecki K.T.4, Zerahn B.5, Hölmich L.R.1

1Herlev Gentofte Hospital, University of Copenhagen, Department of Plastic Surgery, Herlev, Denmark, 2Herlev Gentofte Hospital, University of Copenhagen, Department of Clinical Physiology and Nuclear Medicine, PET-Center, Herlev, Denmark, 3Department of Public Health, University of Copenhagen and Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark, 4Department of Plastic Surgery, Breast Surgery and Burns Treatment, Copenhagen, Denmark, 5Herlev Gentofte Hospital, University of Copenhagen, Department of Clinical Physiology and Nuclear Medicine, Herlev, Denmark

P212 Methyl 5-aminolevulinate photodynamic therapy in the treatment of 112 basal cell carcinomas in 84 Brazilian patientsTaborda V.1

1Centro de Dermatologia e Laser de Bauru, Photodynamic Therapy Unit, Bauru, Brazil

P213 Improving the applicability of guidelines on nonmelanoma skin cancer in frail older adults: A multidisciplinary expert consensus and systematic review of current guidelinesLubeek S.F.K.1, Borgonjen R.J.1, Van Vugt L.J.1, Olde Rikkert M.G.2, Van de Kerkhof P.C.M.1, Gerritsen M.J.P.1

1Radboud University Medical Center, Dermatology, Nijmegen, Netherlands, 2Radboud University Medical Center, Geriatrics, Nijmegen, Netherlands

P214 Lymphoedema following sentinel lymph node biopsy and/or complete lymph node dissection: Impact on health-related quality of lifeGjorup C.1, Grønvold M.2, Dahlstrøm K.1, Drzewiecki K.T.3, Christensen K.B.4, Hendel H.W.5, Hölmich L.R.1

1Herlev Gentofte Hospital, University of Copenhagen, Department of Plastic Surgery, Herlev, Denmark, 2Department of Public Health, University of Copenhagen and Department of Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark, 3Department of Plastic Surgery, Breast Surgery and Burns Treatment, Copenhagen, Denmark, 4Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark, 5Department of Clinical Physiology and Nuclear Medicine, PET Center, Herlev Gentofte Hospital, University of Copenhagen, Herlev, Denmark

P215 Comprehensive clinical data review of patients suffering from Mycosis fungoides with bad outcomePorkert S.1, Venz M.1, Valencak J.1, Jonak C.1

1Medical University of Vienna, Department of Dermatology, Vienna, Austria

P216 Assessment of QOL, illness perception, and illness behavior in 92 patients with primary cutaneous lymphomaPorkert S.1, Lehner‑Baumgartner E.2, Knobler R.1, Riedl E.1, Jonak C.1

1Medical University of Vienna, Department of Dermatology, Vienna, Austria, 2Medical University of Vienna, Department of Clinical Psychology, Vienna, Austria

LATE

-BRE

AK

ING

81

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER


P217 Dermoscopic and Immunohistochemical changes in acquired Melanocytic Nevi following phototherapyAbdel Hay R.1

1Faculty of Medicine, Cairo University, Dermatology, Cairo, Egypt

P218 Clinical outcome of high-risk primary cutaneous squamous cell carcinoma three years after initial treatment at a Scottish dermatology centreNgu S.T.1, Gupta P.1, Gupta R.1, Gupta G.1

1Lanarkshire Centre for Dermatology, Monklands Hospital, Airdrie, United Kingdom

P219 Peripheral blood lymphocyte subsets in melanoma patients treated with ECHO-7 virus and controlOzola E.1, Sālījuma E.1, Doniņa S.1,2

1Rigas Stradins University, Riga, Latvia, 2Riga East University Hospital, Riga, Latvia

LATE

-BRE

AK

ING

82

SCIE

NTI

FIC

PRO

GR

AM

WED

THU

FRI

SAT

INDE

XPO

STER

INDUSTRIAL EXHIBIT ION

List of Exhibitors 85

Exhibition Floor Plan 84

FSA Disclosure Requirement 87

EADO

Get the most recent

information on research

and patient care by

exchanging with our

industry partners.


The industrial exhibition takes place in the Hofburg Galerie, in the Seitengalerie and in the Oberes Platzl.

Exhibition Floor Plan

Festsaal

Seitengalerie

Hofburg Galerie

Geheime RatstubeMarmorsaal Antekammer

Rittersaal

Zeremoniensaal

Lift

Oberes Platzl

Heldenplatz

Heldenplatz

Spe

aker

s P

revi

ew R

oom

Hofburg Lounge

Opening HoursWED, August 31 01:30 PM–07:00 PMTHU, September 1 09:00 AM–05:30 PM FRI, September 2 09:00 AM–05:30 PM SAT, September 3 09:00 AM–12:30 PM

84

IND

UST

RIA

L EX

HIB

ITIO

N


Exhibitor Booth No.

3Gen, Inc./DermLite 7

Amgen 21

Biofrontera Pharma GmbH 11

Bristol-Myers Squibb 22

Canfield Scientific, Inc. 14

Derma Medical Systems Handels- und Entwicklungs GmbH 1

Dermo Scan GmbH 3

Elekta 10

FotoFinder Systems GmbH 4

Heine Optotechnik GmbH & Co. KG 23

IGEA SpA Clinical Biophysics 5

Incyte Corporation 13

Integra 19

MAVIG GmbH VivaScope Systems Confocallasermicroscopy 16

MEDlight 6

Merck-Pfizer Alliance 8

Merck-Pfizer Alliance 17

Mirai Medical 2

MSD 18

Nevisense by SciBase 9

Novartis 20

Provectus Biopharmaceuticals, Inc. 15

Therakos 12

Vielgesundheit 24

Wisepress Medical Bookshop 25

List of Exhibitors

IND

UST

RIA

L EX

HIB

ITIO

N

85

A phase 3 studyof epacadostat and

pembrolizumab

PHASE 3

Patients withunresectable or

metastatic melanoma

ENROLLING

Incyte and Merckcombination

investigational study:ECHO-301/KEYNOTE-252

COMBINATIONINVESTIGATION

Epacadostat is an investigational,novel oral immunotherapy that inhibits indoleamine-2,3-dioxygenase 1 (IDO1)

This study will enroll in the following regions: North America,Central/South America, Europe, Australia, and Other Select Countries

Contact us to learn if any of your patients may be eligible for participation in ECHO-3011-855-4MEDINFO (1-855-463-3463) / [email protected]

OPEN FOR ENROLLMENTNCT02752074

The effi cacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.

© 2016, Incyte Corporation. All rights reserved. INC-1172 06/16

Epacadostat +Pembrolizumab

PembrolizumabRA

ND

OM

IZA

TIO

N

CO-PRIMARY ENDPOINTS

Progression-Free Survival

Overall Survival

S:118 mmS:180 m

m

T:148 mmT:210 m

m

B:154 mmB:216 m

m

EPAC16AGRX4266_2016_ASCO_ECHO_JA_r11.indd 1 6/7/16 11:13 AM


According to the guidelines of the FSA Code of Conduct or other codes, we disclose the financial support of:

Amgen €95,000 (Platinum Sponsor)

Biofrontera Pharma GmbH €2,850 (Exhibition Space)

Bristol-Myers Squibb €102,850 (Platinum Sponsor)

Elekta €4,275 (Exhibition Space)

FotoFinder Systems GmbH €2,850 (Exhibition Space)

Integra €3,800 (Exhibition Space)

Merck-Pfizer Alliance €67,125 (Gold Sponsor)

MSD €95,000 (Platinum Sponsor)

BIOPHARMACEUTICALS, INC.Advancing a New Front

in theWar Against Cancer

Provectus Biopharmaceuticals, Inc.

€19,000 (Bronze Sponsor & Lanyards)

Therakos €2,850 (Exhibition Space)

FSA Disclosure Requirement

87

IND

UST

RIA

L EX

HIB

ITIO

N

A phase 3 studyof epacadostat and

pembrolizumab

PHASE 3

Patients withunresectable or

metastatic melanoma

ENROLLING

Incyte and Merckcombination

investigational study:ECHO-301/KEYNOTE-252

COMBINATIONINVESTIGATION

Epacadostat is an investigational,novel oral immunotherapy that inhibits indoleamine-2,3-dioxygenase 1 (IDO1)

This study will enroll in the following regions: North America,Central/South America, Europe, Australia, and Other Select Countries

Contact us to learn if any of your patients may be eligible for participation in ECHO-3011-855-4MEDINFO (1-855-463-3463) / [email protected]

OPEN FOR ENROLLMENTNCT02752074

The effi cacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.

© 2016, Incyte Corporation. All rights reserved. INC-1172 06/16

Epacadostat +Pembrolizumab

PembrolizumabRA

ND

OM

IZA

TIO

N

CO-PRIMARY ENDPOINTS

Progression-Free Survival

Overall Survival

S:118 mm

S:180 mm

T:148 mm

T:210 mm

B:154 mm

B:216 mm

EPAC16AGRX4266_2016_ASCO_ECHO_JA_r11.indd 1 6/7/16 11:13 AM

Imprint

Scientific OrganizationHubert Pehamberger & Christoph HoellerMedical University ViennaDepartment of DermatologyWähringer Gürtel 18–201090 Vienna, Austria

Legal Organizer & PCOMCI Deutschland GmbH MCI | Berlin Office Markgrafenstrasse 56 10117 Berlin, Germany P: +49 (0)30 204590 F: +49 (0)30 2045950 E: [email protected]

VAT ID number: DE 114406202, Local Court Berlin-Charlottenburg, HRB 100620B Managing Directors: Gunda Stickan, Gerrit Jessen, Andreas Laube

PrintLehmann Offsetdruck GmbH

Picture Credits Cover page: © TTstudio – Fotolia.com (1), © kameraauge – Fotolia.com (2)

Editorial DeadlineAugust 8, 2016

All information is supplied without liability and is subject to change.

88

STRONGER TOGETHER

Combine COTELLIC with Zelboraf to achieve powerful efficacy in patients with BRAF V600(+) metastatic melanoma1

Cotellic® 20 mg film-coated tabletsQualitative and quantitative composition: Each film-coated tablet contains cobimetinib hemifumarate equivalent to 20 mg cobimetinib. Excipient with known effect: Each film-coated tablet contains 36 mg lactose monohydrate. List of excipients: Tablet core: Lactose monohydrate, Microcrystalline cellulose (E460), Croscarmellose sodium (E468), Magnesium stearate (E470b). Film coating: Polyvinyl alcohol, Titanium dioxide (E171), Macrogol 3350, Talc (E553b). Therapeutic indications: Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 “Special warnings and precautions for use” and 5.1 “Pharmacodynamic properties” of the officially published Summary of Product Characteristics). Contraindications: Hypersensitivity to the active substance or to any of the excipients. Marketing Authorisation Holder: Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom General classification of supply: Product on prescription, supply through pharmacies only. Pharmacotherapeutic group: Antineoplastic agents, ATC code: L01XE38For special warnings and precautions for use, interactions with other medicinal products and other forms of interaction as well as information on pregnancy and lactation and on undesirable effects please refer to the officially published Summary of Product Characteristics. December 2015.

1. Larkin J, et al. N Eng J Med 2014; 371:1867-1876. For further information, please visit www.roche-cotellic.com

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported to Bundesamt für Sicherheit im Gesundheitswesen, Traisengasse 5, 1200 Wien, Fax: + 43 (0) 50 555 36207, Website: http://www.basg.gv.at/ and to Roche Austria GmbH, www.roche.at.

PR/COBI/1603/0003 April 2016

13793TW Cotellic Global Advert PORTRAIT A5_v1.indd 1 05/04/2016 17:55

STRONGER TOGETHER

Combine COTELLIC with Zelboraf to achieve powerful efficacy in patients with BRAF V600(+) metastatic melanoma1

Cotellic® 20 mg film-coated tabletsQualitative and quantitative composition: Each film-coated tablet contains cobimetinib hemifumarate equivalent to 20 mg cobimetinib. Excipient with known effect: Each film-coated tablet contains 36 mg lactose monohydrate. List of excipients: Tablet core: Lactose monohydrate, Microcrystalline cellulose (E460), Croscarmellose sodium (E468), Magnesium stearate (E470b). Film coating: Polyvinyl alcohol, Titanium dioxide (E171), Macrogol 3350, Talc (E553b). Therapeutic indications: Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 “Special warnings and precautions for use” and 5.1 “Pharmacodynamic properties” of the officially published Summary of Product Characteristics). Contraindications: Hypersensitivity to the active substance or to any of the excipients. Marketing Authorisation Holder: Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, United Kingdom General classification of supply: Product on prescription, supply through pharmacies only. Pharmacotherapeutic group: Antineoplastic agents, ATC code: L01XE38For special warnings and precautions for use, interactions with other medicinal products and other forms of interaction as well as information on pregnancy and lactation and on undesirable effects please refer to the officially published Summary of Product Characteristics. December 2015.

1. Larkin J, et al. N Eng J Med 2014; 371:1867-1876. For further information, please visit www.roche-cotellic.com

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported to Bundesamt für Sicherheit im Gesundheitswesen, Traisengasse 5, 1200 Wien, Fax: + 43 (0) 50 555 36207, Website: http://www.basg.gv.at/ and to Roche Austria GmbH, www.roche.at.

PR/COBI/1603/0003 April 2016

13793TW Cotellic Global Advert PORTRAIT A5_v1.indd 1 05/04/2016 17:55

*IndicationIMLYGIC® is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease (see sections 4.4 and 5.1 of the Summary of Product Characteristics).1

© 2016 Amgen Inc. All rights reserved. EUHQ-P-678x-0116-122547. August 2016

For patients with regionally or distantly metastatic melanoma, stage IIIB, IIIC and IVM1a*

INJECT THE LESION.IGNITE AN IMMUNE RESPONSE.THAT’S THE PRECISION OF IMLYGIC®.

For further information please consult the Summary of Product Characteristics (SmPC).Reference: 1. Imlygic Summary of Product Characteristics.

NOW APPROVEDIN THE EU

IMLYGIC®(talimogene laherparepvec)

FachkurzinformationImlygic 106 Plaque-bildende Einheiten (PFU)/ml InjektionslösungImlygic 108 Plaque-bildende Einheiten (PFU)/ml InjektionslösungQualitative und Quantitative Zusammensetzung: Jede Durchstechflasche enthält 1 ml entnehmbares Volumen Imlygic in einer nominalen Konzentration von 1 x 106 (1 Million) respektive 1 x 108 (100 Millionen) Plaque-bildenden Einheiten (PFU)/ml. Sonstige Bestandteile mit bekannter Wirkung: Jede Dosis von 4 ml enthält ungefähr 30 mg (1,3 mmol) Natrium und 80 mg Sorbitol.Liste der sonstigen Bestandteile:Dinatriumphosphat-Dihydrat, Natriumdihydrogenphosphat-Dihydrat, Natriumchlorid, Myo-Inositol, Sorbitol (E420), Wasser für Injektionszwecke.Anwendungsgebiete: Imlygic ist indiziert zur Behandlung von Erwachsenen mit nicht resezierbarem, lokal oder entfernt metastasiertem Melanom (Stadium IIIB, IIIC und IVM1a) ohne Knochen-, Hirn-, Lungen- oder andere viszerale Beteiligung.

Gegenanzeigen: Patienten mit einer Vorgeschichte einer Überempfindlichkeit gegen Talimogen laherparepvec oder einen der sonstigen Bestandteile.• Patienten, die schwer immungeschwächt sind (z. B. Patienten mit schwerer

angeborener oder erworbener zellulärer und/oder humoraler Immunschwäche).Pharmakotherapeutische Gruppe: Antineoplastische und immunmodulierende Mittel, ATC-Code: L01XX51.Inhaber der Zulassung: Amgen Europe B.V., 4817 ZK Breda, NL, Vertreter in Österreich: Amgen GmbH, 1040 Wien.Verschreibungspflicht / Apothekenpflicht: Rezept- und apothekenpflichtig. Stand der Information: Juli 2016Weitere Angaben zu Dosierung und Dauer der Anwendung, besonderen Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit sowie zu Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation.

Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinformation.

IMLYGIC_PRESS_AD_+API_AUSTRIA_A5_020816.indd 1 03/08/2016 14:04